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ABSTRACT
Becker, Larry J., M.S., 1977 Microbiology
Characterization of the Immune Response in Mice Treated
With Material Toxic for Macrophages (127 pp.)
Director: Jon A, Rudbach
RML mice were treated with Min-U-Sil or carrageenan, 
both of which were toxic for macrophages. After 6 h, 
the mice were immunized intravenously (i.v.) with either 
lipopolysaccharide (LPS) or sheep red blood cells (SRBC). 
The kinetics of the subsequent antibody responses were 
determined by hemagglutination. Treatment with these 
toxins prior to immunization did not suppress the pri­
mary antibody response to either antigen nor did it impair 
priming for a secondary antibody response. In fact, 
enhanced primary antibody responses were obtained in 
some macrophage impaired mice. The outcome depended on 
the dose of antigen used to challenge mice and the time 
of immunization after macrophage impairment. Macro­
globulin (19 S) antibody production was found to be 
prolonged in mice immunized during macrophage impair­
ment. Secondary type antibody responses to LPS could be 
elicited with one dose of LPS, if given 21 days after 
macrophage impairment. From these results, a regulatory 
role for the macrophage in the afferent limb of the 
humoral immune response was proposed.
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CHAPTER I 
INTRODUCTION
Recent investigations of the initiation and develop­
ment of the immune response through studies of cellular 
interactions have led to an increased awareness of the com­
plexity of the immune system. Attempts to define the role 
of these cellular interactions in the initiation of the 
immune response have become an active area of research in 
modern immunology. Both cell-mediated immunity and anti­
body production appear to be direct results of previous 
cellular collaboration. The term "antigen reactive unit" 
(ARU), has been coined by Pross and Eidnger (64) to define 
the minimum complex of cells and factors necessary to pro­
duce a detectable immune response in reaction to antigenic 
stimulation. A full understanding of the ARU is essential 
in delineating the immune response at the molecular level, 
as well as offering a means of practical immunerégulâtion.
Macrophages are perhaps the most controversial cellu­
lar component of the ARU. Since the time of Metchnikoff, 
the role of macrophages in a host's resistance to disease 
has remained a controversial area of research. Early 
studies into the understanding of antibody formation, 
apparently indicated that the macrophages were responsible 
for both the uptake of antigen and synthesis of antibody 
(cf 45). As a consequence, a great part of the research in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
immunology was devoted to evaluating the uptake of antigen 
by macrophages, in addition to studying the physiology of 
macrophages. Once it was recognized that lymphocytes and 
plasma cells were the cells involved in antibody syn­
thesis (cf ^5), the interest in macrophages subsided 
momentarily. However, the extensive investigations of the 
mechanisms of lymphocyte interactions and the molecules re­
leased from immunocompetent lymphocytes have regenerated an 
interest in determining the precise role(s) that macro­
phages may play in the development of optimal immune re­
sponses (35). The macrophage now appears to be a key cell 
in the efferent limb of cell-mediated immunity (57, 90). 
However, its involvement as an essential cellular component 
of the afferent limb of humoral immunity or even of cell- 
mediated immunity has remained controversial (83).
Numerous mechanisms have been proposed for the 
function(s) of macrophages as possible auxiliary cells in 
the afferent limb of the immune response. Some investi­
gators view macrophages as a scavenger cell, whose primary 
purpose is to engulf antigen and break it down into 
immunologically nonreactive products (24, 61). In this 
role, macrophages would appear to act as a safeguard of 
the immune system protecting the host from antigenic 
overdose (13). It has been shown by Pujiwara and Cinader 
(34), and by others (18) that a reduction in the macro­
phage population of a strain of mice which were
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
resistant.to induction of tolerance led to the development 
of tolerance when these animals were subsequently chal­
lenged with tolerogen.
Other investigators felt that, in addition to the role 
of scavenger cells, macrophages also might play a key role 
in the afferent limb of humoral immunity (26, 33i 35i 38,
56, 63). Since macrophages themselves were unable to pro­
duce antibodies, it had been suggested that they might 
transmit some form of information about the antigen to the 
lymphoid cells and in the process "educate” them. It was 
hypothesized that these "educated" lymphoid cells then would 
be capable of generating a specific antibody response. 
Fishman (30) and other investigators (1, 10, 39) have 
suggested that macrophages produced antigen-specific RNA 
which coded for the specific antibody to be produced. 
Feldmann and Palmer (27) proposed that macrophages de­
graded the antigen into fragments, which were capable of 
stimulating directly the lymphoid cells. Other investiga­
tors (3, 23, 32, 85, 86, 8?) have presented data which 
suggested that the macrophage enhanced antigenicity by 
"processing” the antigen and modifying it to a highly 
immunogenic form.
Unanue and co-workers (88) have proposed that small 
quantities of antigen resisted phagocytosis and tended to 
persist on the surface of macrophages. Unanue (88) and 
Nossal (59) theorized that the immune response operated
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best when antigen was concentrated and focused by mono­
nuclear phagocytes. Still others have proposed that 
macrophages released nutritive and regulatory factors 
that modulated lymphocyte responsiveness to antigenic 
stimulation (19). Many substances have been found which 
were released by macrophages in what appears to be a 
true secretory process. These included numerous enzymes, 
complement proteins and a number of factors defined only 
by their biological activity on other cells (15» 16, 84, 
89). Recently, it has been demonstrated that macrophages 
could be replaced by their own culture supernatant fluids 
or by 2-mercaptoethanol when tissue culture systems were 
employed to measure antibody responses to certain anti­
gens (19, 44, 51). The possibility that 2-mercaptoethanol 
might stimulate directly the transformation of mouse 
lymphoid cells into blast cells had been evaluated. How­
ever, there was no evidence that 2-mercaptoethanol was a 
mitogen; rather, it appeared to act by maintaining lympho­
cyte viability and function.
Several investigations have focused on the role of 
macrophages m  vivo in the immune response. In general, 
these studies have involved macrophage transfer experiments 
(75, 78, 82) or have employed the use of agents which 
either blockade the reticuloendothelial system (RES)
(29, 70, 72) or were selectively toxic for macrophages 
(8, 52, 78, 81). Studies of the immune response to antigen
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administered at the time of RES blockade (8, 29, ?1) have 
determined that the extent and duration of blockade was 
dependent upon the concentration and type of blocking 
agent employed. Sabet and co-workers (71, 72) have shown 
a 20 fold depression in the number of antibody-forming 
cells when the blocking agents were given a day or two be­
fore subsequent challenge with antigen. Studies in which 
carrageenan, a high molecular weight polygalactose, was 
employed as a macrophage toxin indicated that the genera­
tion of the immune response was dependent upon the route 
of subsequent antigenic dose (8), If antigen was admin­
istered i.v. when carrageenan was given i.p. there was no 
change in the antibody response. However, when antigen was 
injected i.p. a decreased antibody response resulted.
In other studies, the immunogenicity of free antigen 
versus antigen associated with macrophages has been com­
pared. Generally, it was found that antigens which were 
phagocytized poorly in vivo by macrophages induced at 
least a 10 fold increase in the immune response when pre­
sented as the macrophage-associated form rather than the 
free form (55» 77, 85). However, a different situation 
was encountered with antigens that were strongly phago­
cytized by macrophages in vivo. In this situation the 
free form of the antigen induced a 2 fold increase in the 
immune response when compared to a comparable amount of 
the macrophage-associated antigen (21, 82).
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Katz and Unanue (4?) have shown that the increased 
immunogenicity of macrophage-associated antigen may not 
necessarily he due to the processing of antigen by macro­
phages. In experiments when hapten-protein conjugates 
were used, it was found that fibroblasts were comparable 
to macrophages in their capacity to present antigen in an 
increased immunogenic form. These authors postulated that 
T-lymphocytes were triggered best by antigen bound to any 
cell and that after this step, the activated T-lymphocytes 
regulated the triggering of B-lymphocytes.
On the other hand, there were other situations in 
which macrophages were shown to have an immunologically 
suppressive effect. A decreased immune response was ob­
tained when antigen was injected into the peritoneal cavity 
of mice which had been stimulated previously so that the 
ascites fluid contained a high concentration of macrophages 
{31). If iodoacetate, an inhibitor of phagocytosis, was 
injected into the peritoneal cavity prior to the injection 
of antigen, the immune response was restored (31).
Although the experimental protocols and model systems 
employed were highly variable, some general characteriza­
tions about the immune response in vivo could be made from 
these studies. In order to demonstrate immunological 
responsiveness in vivo, immunocompetent lymphocytes were 
necessary. That is to say when antigen-associated macro­
phages were transferred into immunologically tolerant mice,
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or into mice in which lymphoid function had been impaired 
by X-irradiation, there was no detectable immunological 
response (21, 55). Investigators also have demonstrated 
up to a 5 fold increase in antibody titer, when antigen 
was associated with viable syngenic macrophages as opposed 
to non-viable, allogeneic or xenogenic macrophages (53»
82), Thus, these data suggested that viable genetically 
compatible macrophages might also be necessary for immuno- 
competency in vivo. But, in contrast to the above studies, 
it has been found also that the immune response could be 
inhibited partially in vivo. when normal macrophages were 
injected simultaneously with macrophages containing 
antigen (78, 87).
Thus, despite this great amount of experimental data 
and proposed mechanisms, the role of macrophages in the 
generation of antibodies has remained unresolved. Neither 
the use of in vitro nor in vivo systems appeared to have 
proven a definitive role for the macrophages in the 
afferent limb of humoral immunity. Conflicting evidence 
as well as conflicting conclusions continued to be elicited 
by various investigations. It was still unclear whether 
macrophages were absolutely essential in the induction of 
the immune response or just facilitated antigen-stimulated 
lymphocyte transformation.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Statement of Purpose
The purpose of this study was to determine if a 
reduction in the number of sessile macrophage as well as a 
reduction of their function would alter the subsequent 
antibody response. More specifically, there were two areas 
of concern in this study: (1) to determine the extent and
duration of macrophage impairment induced by various 
treatment; and (2) to characterize the immune status of the 
mouse at the time of maximum macrophage impairment.
The phagocytic activity of the RES in mice was charac­
terized following varying regimens of treatment with 
crystalline silica and carrageenan. The kinetics of the 
primary antibody response were characterized in macrophage- 
impaired mice and were compared with those of normal mice. 
The distribution of the antigen in the macrophage-impaired 
mouse was investigated also. Subsequently the ability of 
the macrophage-impaired mouse to prime for a secondary 
antibody response was evaluated. Finally, in several cases, 
the qualitative type of antibody engendered in the response 
was determined.
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■CHAPTER II 
MATERIALS AND METHODS
Animals
All experiments were performed on 5-8 week old Swiss- 
Webster derived mice of both sexes obtained from the Rocky 
Mountain Laboratory (RML) stock, Hamilton, Montana. The 
mice were housed in groups of 5 and allowed food and 
water a^ libitum.
Preparation of carrageenan
•pCalcium carrageenan in the form of Sea Kem-9 was 
generously donated by Dr. Donald Renn (Marine Colloids, 
Rochland, Maine). Prior to injection, the dry carrageenan 
was weighed, placed in a sterile vial and resuspended to 
the desired concentration with warm (37°C) sterile phos­
phate buffered saline (PBS) (0.15 M NaCl, 0.0033 M PÔ ;̂ 
pH 7.2).
Preparation of silica
Silica particles, (MIN-U-SIL, Whittaker, Clark and 
Daniels, Inc., NY, NY) of less than 5 urn in average size, 
were used for all in vivo studies. Further sizing 
fractionation was done according to the method of Larson 
(50). Briefly, 50 g of silica were suspended in 300 ml
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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of distilled water and subjected to ultrasonic vibrations 
(Bronson, Danbury, Conn.) for ]0 sec. This suspension 
was diluted to a total volume of 1 ^ with distilled water, 
placed in a 1 ̂  graduated cylinder and allowed to settle 
at room temperature (25°C) for 24 h. Pour 250 ml aliquots 
were then aspirated and placed in separate centrifuge 
tubes. Fraction III (BUS) corresponding to the 500-750 ml 
portion from the top, was washed two times with distilled 
water and allowed to dry in a warm (60°C) oven for 48 h.
It was determined by optical measurement, that BUS consisted 
of particles of the following sizes: 2.1 urn x 2,8 urn (80^),
1.4 urn X 3.5 nm (10^), and 1.4 urn x 2.1 urn (10^) (50).
Prior to injection, the dry MUS was weighed, placed in a 
sterile vial, autoclaved and resuspended to the desired con­
centration with sterile PBS.
Preparation of antigens
LPS from E. coli 0113. The lipopolysaccharide (LPS) 
used in these studies was a phenol-water extract of 
Escherichia coli 0113 (Braude strain) prepared as described 
previously by Rudbach et al. (69).
Sheep red blood cells (SRBC). SRBC preserved in 
Alsever's solution were obtained from the Colorado Serum 
Company (Denver, CO). When prepared as an antigen for 
immunization, the SRBC were washed thrice in cold (4°C) PBS
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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and the packed cells were reconstituted to the desired con­
centration with cold PBS,
Collection of sera for hemagglutination assays
Whole blood was obtained from mice anesthetized with 
ether by exsanguination following an axillary incision.
The blood was allowed to clot at room temperature for 
approximately 1 h and then at 4°C overnight. The serum was 
harvested by centrifugation (1,000 x g for 10 min), dis­
pensed into vials, heated to 56^0 for 30 rain and stored 
at -20°C.
Quantification of humoral antibodies
Antibodies specific for the LPS determinant were 
measured by passive hemagglutination (67). Briefly, SRBC 
coated with LPS extracted from E. coli 0113 were used as 
indicator cells (58). For sensitization, 1 mg of LPS was 
dissolved in 1 ml of 0.1 M phosphate buffer (pH 7.4) and 
then placed in a boiling water bath for 2 & h. Sensitized 
SRBC were prepared by combining 0.25 ml of packed, washed 
SRBC, 9.0 ml PBS and 1 ml of the boiled LPS. This mixture 
was then incubated at 37^0 for 30 min with frequent mixing. 
The cells were then washed thrice in cold PBS and finally 
resuspended to a total volume of 0.5 ml with micro­
titer diluent (PBS containing 1% heat inactivated, SRBC-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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absorbed normal rabbit sera). The sensitized SRBC were 
used immediately after preparation.
Antibodies specific for SRBC were measured by direct 
hemagglutination. SRBC were washed thrice in cold PBS and 
0.25 ml of the packed SRBC were then suspended to a total 
volume of 50 ml in microtiter diluent. The SRBC were used 
immediately after preparation.
To each well of a microtiter plate (Linbro Chemical 
Company, Inc., New Haven, CT) 0.05 ml of microtiter diluent 
was added and serial two-fold dilutions of the sera were 
made with 0.05 ml micro-dilutors (Cooke Engineering Co., 
Alexandria, VA). Next, 0.05 ml of SRBC or sensitized 
SRBC suspended to a final concentration of 0.5^ were added 
to each well, the plate was gently agitated, covered and 
placed in a humid chamber. Hemagglutination was recorded 
after incubation of the plates for 2 h at 25°C and over­
night at 4°C.
Titers were expressed as values of x derived from the 
equation, x = log^ (HD/2), where HD was the reciprocal of 
the highest dilution of sera which produced hemagglutin­
ation. Thus, the titer was the tube number of the end­
point when the first tube contained a i dilution of anti­
serum. Sera which gave no hemagglutination at the lowest 
dilution tested were arbitrarily assigned a titer of 0, 
ie., a dilution of i. All serum samples were tested in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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duplicate and titers were expressed as the average titer 
of both tests.
Treatment of sera with 2-mercantoethanol (2-ME)
Sera were treated with 2-ME to inactivate the hemag- 
glutinating activity of IgM antibodies. To the first well 
of a microtiter plate were added 25 ul of serum, 25 ul PBS 
and 50 ul of 0.2 M 2-ME (Sigma Chemical Co., St. Louis, MO),
This mixture was allowed to incubate at 37°C for 30 min in
a sealed humid chamber. After incubation, 0.05 ml of the 
microtiter diluent was added to the remaining wells and 
the sera were diluted and assayed as described previously. 
These experiments were interpreted on the assumption that 
the residual hemagglutinating antibodies present in the sera 
treated with 2-ME were all of the IgG immunoglobulin class.
PhaTOCvtic activity in vivo as measured by colloidal 
carbon clearance
RES function, as demonstrated by the phagocytic 
activity in vivo. was studied in both normal and treated 
mice. Data were obtained by measuring the ability of mice 
to clear a solution of colloidal carbon from their blood by 
using a modified procedure of Biozzi et al. (9). The
colloidal carbon (Pelikan Cll/l431a, Koh-I-Noor, Bloomsbury,
NJ) was suspended to a final concentration of 10 mg/ml in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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PBS containing 1% gelatin (Baker Chemical Co., Phillipsburg, 
NJ). The suspension was dispensed into sterile vials and 
frozen at -20^C until used. Test animals were weighed 
(Mettler Model P120, Mettler Instruments, Princeton, NJ) 
and then injected intravenously with 0.1 mg of prewarmed 
(37°C) colloidal carbon per gram body weight. The mice 
were anesthetized with ether (Mallinchrodt Chemical Co,,
St. Louis, MO) and were bled from the retro-orbital 
plexus at 5 and 15 min after the carbon injection. At 
each bleeding 0.02 ml of blood was obtained in disposable 
pipets (Coming, Corning, NY) that had been rinsed pre­
viously with a heparin (Riker Lab, Inc., Northridge, CA) 
solution of 500 units/ml. The blood samples were then 
lysed in 2.0 ml of a 0.1^ NagCO^ (Baker Chemical Co., 
Phillipsburg, NJ) solution and their optical densities were 
determined at 650 nm with a Coleman Jr. spectrophotometer 
(Coleman Instruments, Maywood, IL). After the 15 min blood 
samples were obtained, the mice were sacrificed and the wet 
weights of the liver and spleen were determined.
The phagocytic index (K) was determined for each mouse 
by the following formula (52),
K = Log^Q OD at 5 min - Log^Q OD at 15 min
10 min
The phagocytic index corrected for differences in body and 
organ weight ((%:), was determined for each mouse by the
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following formula (52).
K X (liver weight + spleen weight)
' total body weight
Median Lethal Dose (LD^^) of treated and normal mice
LD^q for LPS extracted from E. coli 0113 was deter­
mined for both normal and treated animals. MUS-treated 
mice received 10.0 mg of MUS contained in a total volume of 
0.2 ml of PBS, intravenously (i.v.). These mice were then 
injected intraperitoneally (i.p.) with LPS contained in 0.2 
ml PBS. Carrageenan-treated animals received 5.0 mg of 
carrageenan contained in 0.5 ml PBS i.p.; this was followed 
by the injection of LPS i.p. Normal mice were given PBS 
in the same volumes and routes as the MUS and carrageenan, 
followed by the injection of LPS i.p. Additional controls 
included mice that received only MUS or carrageenan. All 
experiments were performed on groups of 10 mice and were 
terminated after 72 h. Percent mortality of mice receiving 
both MUS and LPS was computed by the following formula, for 
each dose of LPS injected; mortality in groups receiving 
MUS and LPS minus mortality in groups receiving only MUS = 
mortality due to LPS. Mortality data were analyzed by 
the Formal Probit Method (4).
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In vitro study of -peritoneal macrophages
Peritoneal exudate cells (PEC) were stimulated by an 
injection of 2.0 ml of sterile y/> thioglycolate broth (Difco 
Laboratories, Detroit, MI) into the peritoneal cavity of 
mice. After 72 h, the mice were treated with either 10 mg 
of MUS i.v. or 5 mg of carrageenan i.p. Twenty-four hours 
after treatment, the mice were sacrificed and the PEC were 
harvested as follows. The abdominal area was cleansed with 
alcohol and 5.0 ml of sterile double strength Eagles Minimal 
Essential Media (EMEM) (Grand Island Biological Company, 
Grand Island, NY) was injected into the peritoneal cavity. 
The abdominal area was massaged, and the peritoneal fluid 
was aspirated and placed into a chilled (4°C) silicone 
(Sili-Clad, Clay Adams, Parsippany, NJ) coated tube. The 
harvested PEC were then assayed for their jjn. vitro phago­
cytic activity by the method of Cutler (22). Briefly, the 
PEC were washed thrice in EMEM, counted in a hemacytometer 
and adjusted to a final concentration of 1.0 x 10^ cells/ml 
with EMEM containing 10^ (v/v) fresh frozen normal mouse
sera (PFNMS). A 0.5 ml volume of this suspension was then
2dispensed onto a 22 mm plastic cover slip and placed in a 
37°C incubator for 30 min. After this incubation, the 
cover slip was rinsed vigorously thrice in EMEM to remove 
the non-adherent cell populations. Then 0.5 ml of EMEM 
containing 10^ FPMMS and 2 x 10^ Candida stellatoidea
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cells/ml was dispensed onto the cover slip and this was 
followed by incubation at 37°C for 60 min. The cover slip 
was rinsed thrice with EMEM and then overlayed immediately 
with 0.5 ml of EMEM containing 10^ FPNMS, and incubated at 
37°C for 30 min. After this incubation, the cover slip was 
rinsed with PBS, air dried, stained with Wright's stain 
and observed under oil immersion. At least 200 cells/cover 
slip were counted and the percentage of cells that had 
phagocytized at least two yeast cells was determined.
The rest of the original cell suspension was centri­
fuged and resuspended in 0.2 ml of FPNMS. From this con­
centrated suspension slides were prepared, stained with 
Wright'8 stain and differential counts were performed.
Preparation of ^^Cr labeled LPS
LPS was labeled with hexavalent ^^Cr by a modification 
of the method described by Braude et al. (11). Ten mg of 
LPS was dissolved in 5 ml water containing 1.1 millicuries 
of Nâ '̂ ĈrOĵ  (E. R. Squibb and Sons, Inc., Seattle, WA) and 
incubated at 37°C for 48 h. Following incubation, the 
solution was dialyzed against 0.001 M NagPO;̂  ̂(pH 7.2) at 
4°C. The dialysate was changed daily until the radio­
activity of the dialysate was constant for 3 days in suc­
cession. The contents of the dialysis tube were counted in, 
order to determine the specific activity, and the labeled
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LPS was diluted to a concentration of 50 ug/ml with PBS. 
Immediately prior to each experiment, 0.2 ml of the labeled 
LPS was counted to determine the specific activity.
All animals were injected i.v. with the labeled LPS 
contained in a total volume of 0.2 ml PBS. Radioactivity 
of the whole blood and organs were measured in a well-type 
scintillâtion counter (Nuclear-Chicago Corp., Des Plaines, 
XL) with an efficiency of approximately %  for ^^Cr. To 
measure radioactivity, samples were placed in a glass tube 
and inserted into the crystal. Samples were counted and 
corrected for background and decay.
Test for lytic activity of WUS and carrageenan treated sera
Whole blood was collected from mice anesthetized with 
ether and allowed to clot for 1 h at 4^0. The sera were 
harvested, pooled and heat inactivated at 56^0 for 30 min. 
Serum samples of 1 ml were added to 0.2 ml of either MUS or 
carrageenan; following this, 0.2 ml of a 10^ SRBC suspen­
sion was added and the mixtures were incubated for 3 h at 
37°C. After incubation, the samples were centrifuged 
(1000 X g for 10 min) to sediment the SRBC, and the super­
natant fluids were removed and assayed for hemoglobin levels
Hemoglobin levels
Hemoglobin levels were determined by a modification of
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the method of Hanks et al. (41). Briefly, 10 ul of sera 
were added to individual tubes containing 0.5 ml of a 
benzidine base (Fisher Scientific Co., Pittsburgh, PA) pre­
pared in 90fo acetic acid (E. I. DuPont, Inc., Wilmington, 
DA). To this was added 0.5 ml of a 1^ hydrogen peroxide 
solution (J, T. Baker Chemical Co., Phillipsburg, NJ). The 
contents of the tubes were mixed vigorously and then incu­
bated at 25^C for 20 min. After incubation, 5.0 ml of 10^ 
acetic acid were added to each tube. Following an addition­
al incubation period of 10 min at 25°C, the absorbance of 
the solutions were measured on a Coleman Jr. spectro­
photometer at 515 ^m against a 10^ acetic acid blank. All 
samples were analyzed in duplicate.
Standard hemoglobin solutions were prepared by washing 
SRBC thrice with PBS. The washed packed SRBC were lysed 
with an equal volume of water followed by the addition of 
0.5 ml toluene (Eastman Organic Chemicals, Rochester, NY), 
This solution was centrifuged (12,100 x g) for 10 min and 
the hemoglobin concentration of the supernatent fluid 
determined by the cyanmethemoglobin method (cf 5). Standard 
solutions of 5» 10, 15 and 20 mg hemoglobin/dl were pre­
pared from the stock solution.
Collection of sera for passive transfer and enzymatic assays
Whole blood was obtained from mice and was allowed to
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clot at 4°C for 1 h. The sera was harvested by centri­
fugation (1000 X g for 10 min) at 4°C and enzymatic assays 
performed immediately. Sera to be used for passive trans­
fer were warmed to 37°C for 5 min and 1.0 ml samples were 
injected into the peritoneal cavity of normal mice.
Acid phosohatase (EG 3.1,3.3) determination
Acid phosphatase levels were determined on fresh 
pooled sera by the modified method of Roy et al. (66). 
Duplicate determinations of all samples were performed on a 
DuPont Automatic Clinical Analyzer (ACA, Model 700,000 
DuPont Co., Wilmington, DE). Briefly, under acidic condi­
tions, thymolphthalein monophosphate was hydrolyzed by 
phosphatase to produce thymolphthalein. Thé reaction was 
terminated with NaOH, and the absorbance read at 600 nm.
The absorbance at 600 nm due to the thymolphthalein was 
proportional to the activity of the acid phosphatase in 
the sample.
Lactate dehydrogenase (EC 1.1.1.27) determination
Lactate dehydrogenase (LDH) levels were determined on 
fresh pooled sera by the procedure of Gay et al. (36). 
Duplicate determinations of all samples were performed on 
a DuPont Automatic Clinical Analyzer (ACA). The method can 
be described briefly as follows: LDH catalyzed the
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oxidation of L-lactate to pyruvate with the simultaneous 
reduction of nicotinamide-adenine dinucleotide (NAD) to the 
reduced form of nicotinamide-adenine dinucleotide (NADH). 
Since other reactants were present in non-rate limiting 
quantities, the change in absorbance at 340 nm due to the 
appearance of NADH was directly proportional to the LDH 
activity.
Plague-forming cell assay
The number of direct plaque-forming cells (PPG) 
specific for LPS were quantified by a hemolytic plaque 
assay (53). SRBC coated with LPS extracted from E. Coli 
0113 were employed as indicator cells. Spleens were re­
moved from mice and a single cell suspension prepared by 
pressing the minced spleens through a 40 mesh stainless 
steel screen into cold (4°C) double strength (2X) Eagle's 
Medium (Grand Island Biological Co., Grand Island, NY) 
buffered with 1.0 M Tris-HCl, The cell suspension was 
washed once with 2X Eagle's, incubated for 10 min at 25^C 
with 0.83^ ammonium chloride (NHĵ Cl) to lyse the erythro­
cytes, and washed a second time with 2X Eagle's. There­
after, the cells were resuspended in 3.O ml of IX Eagle's 
and appropriate plating dilutions were prepared in IX 
Eagle's.
Individual tubes containing 2.0 ml of 0.8^ agar
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(Bacto Agar; Difco Laboratories, Inc., Detroit MI) in IX 
Eagle's and 0,2 ml of 1% DEAE-dextran (Pharmacia Pine 
Chemicals, Uppsala, Sweden) were prepared in a 4^°C water 
bath immediately prior to plaquing. Next, 0,2 ml of a 
JOfo suspension of SRBC coated with LPS and 0.2 ml of the 
spleen cell suspension were added. The tubes were inverted 
thrice and the contents poured into plastic petri plates 
and allowed to solidify. The plates were incubated in a
humid chamber for 2 h at 37°C. Following incubation. 3.0 ml
of guinea pig complement (BBL Division of Bio-Quest,
Cockeyville, MD) diluted 1/10 in a standard complement
diluent (6l) was added to each plate. The plates were then 
incubated for 45 min at 37^C» after which the number of 
plaques on the plates were counted. Duplicate plates of the 
same test cell suspension were made and the average number 
of PPG was calculated. The PPG responses of mice were ex­
pressed as the number of PPC/spleen.
Statistical analysis
When applicable, data were analyzed by the Student's 
t test (4), Differences between groups were considered 
significant if p <0.05. Antibody titers were considered 
to be different if the end points were at least two tubes 
apart.
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CHAPTER III 
RESULTS
Effects of MUS on the •phaorocytic activity of the RES
Initial experiments were designed to determine the 
route of injection and amount of MUS which would produce 
maximum impairment of the RES phagocytic activity. Evalua­
tion of phagocytic activity in vivo was based upon the 
ability of test mice to clear carbon particles from the 
peripheral blood. Figure 1 demonstrates the phagocytic 
activity of the RES following the i.p. injection of varying 
concentrations of MUS. The ability of test mice which re­
ceived MUS i.p. to clear carbon from the blood was essen­
tially the same as mice which received i.p. PBS. Likewise, 
multiple i.p. injections of MUS on successive days did not 
affect the rate of carbon clearance from the peripheral 
blood.
Unlike the i.p. route, a single injection of MUS i.v. 
produced a significant (p< 0.05)reduction in the rate of 
peripheral blood clearance of carbon (Fig. 2). A dose of 
10 mg of MUS injected i.v. reduced the rate of clearance 
of carbon from the blood by Neither multiple in­
jections nor increased amounts of MUS suppressed phagocytic 
activity. Intravenous injections of MUS in amounts greater 
than 20 mg were fatal to more than ^0% of the experimental .
23
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Fig, 1. Phagocytic activity of the RES following i.p. 
injection of varying amounts of MUS. All mice were tested 
for RES activity 24 h after the final injection of TWS. 
Normal mice received an equal volume of PBS. Each value 
represents the arithmetic mean of 5 mice.
Symbols:
Single injection of MUS
|̂~ I MUS injected on 2 consecutive days 
MUS injected on 5 consecutive days
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Fifr. 2. Phagocytic activity of the RES following i.v. 
injection of varying amounts of MUS, All mice were tested 
for RES activity 24 h after the final injection of MUS, 
Normal mice received an equal volume of PBS. Each value 
represents the arithmetic mean of 5 mice.
Symbols :
Single injection of ÎWS 
I—  — I MUS injected on 2 consecutive days
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animals (data now shown). Therefore, 10 mg of MUS injected
i.v, was chosen as the standard regimen. Hereafter, 10 mg 
of MUS injected i,v. will be referred to as the standard 
dose of MUS.
Effects of carrageenan on the nhaerocvtic activity of 
the RES
Similar experiments were designed to evaluate the 
ability of carrageenan to suppress RES activity. The route 
of injection and amount of carrageenan necessary to 
achieve maximum impairment of the RES were determined from 
the peripheral blood carbon clearance data. Figure 3 
represents the phagocytic activity of the RES following the
i.p. injection of carrageenan. All amounts of carrageenan 
administered i.p, produced a significant (p < 0.03) sup­
pression of the ability of the RES to clear carbon from 
the blood. Maximum suppression of the phagocytic activity 
of the RES was obtained with 5 mg carrageenan. Doses 
greater than 5 mg did not further suppress RES activity 
but often produced ablepsia and acronecrosis,
Figure 4 represents the phagocytic activity of the RES 
following the i.v. injection of carrageenan. All concen­
trations of carrageenan injected i.v. produced significant 
(p<0.05) suppression of RES activity, however, con­
centrations of 2 mg when administered i.v. were fatal to
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Pig. 3. Phagocytic activity of the RES following i.p. 
injection of varying amounts of carrageenan. Test mice 
received a single i.p. injection of carrageenan and were 
tested for RES activity 2^ h later. Normal mice received 
an equal volume of PBS. Each value represents the arithmetic 
mean of 5 mice.
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Fig, 4. Phagocytic activity of the RES following i.v. 
injection of varying amounts of carrageenan. Test mice 
received a single i.v. injection of carrageenan and were 
tested for RES activity 24 h later. Normal mice received 
an equal volume of PBS. Each value represents the 
arithmetic mean of 5 mice.
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100^ of the test mice. Therefore, a dose of 5 mg. carra­
geenan injected i.p. was used in all further experiments; 
hereafter this will he referred to as the standard dose of 
carrageenan.
Duration of suppression of RES activity following treatment 
with MUS
The duration of suppression of RES activity by MUS was 
evaluated by injecting a group of mice with the standard 
dose of MUS and subsequently, testing them in groups at 
varying intervals for their ability to clear colloidal 
carbon. As shown in Fig., , significant (p<0,05) suppresr- 
sion was observed by 2 h after the administration of MUS, 
and RES activity remained suppressed for 4 days. Maximum 
suppression was observed at 6 h and continued at this level 
for at least 24 h. A gradual recovery of RES activity 
occurred following the single i.v, dose of MUS and clearance 
values, equivalent to those obtained in normal mice, were 
obtained by day 5.
Duration of RES sunnression following treatment with 
carrageenan
The duration of suppression of the RES following 
carrageenan treatment was evaluated in the same manner as 
MUS. Mice were injected with the standard dose of
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Fig. 5. Duration of RES suppression following treatment 
with MUS, Test mice received a single i.v. Injection of 
10 mg MUS at time 0 and were tested at various times for 
their ability to clear carbon from the peripheral blood. 
Normal mice received an equal volume of PBS. Each value 
represents the arithmetic mean of 5 mice.
Symbols ;
L / /  /  Normal range of oC value
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carrageenan, and then tested at varying times for their 
ability to clear colloidal carbon from the peripheral blood. 
Results are shown in Fig. 6. Within 2 h of the carrageenan 
injection, RES activity was suppressed significantly 
(p< 0,05) and remained suppressed for 4 days. Maximum 
suppression was observed at 6 h and continued at this level 
for 48 h.
When Pig, 5 and 6 are compared, the kinetics of sup­
pression obtained after MUS and carrageenan treatment 
seemed to be similar. Both phagocytic indexes dropped to a 
minimum mean phagocytic clearance value of 0.0? + O.OO5 
within 6 h after treatment. The suppression persisted 24 h 
with MUS and 48 h with carrageenan, after which a linear 
recovery occurred and normal phagocytic clearance values 
were obtained by day 5.
Effects of MUS and carrageenan on phagocytosis in vitro
Since phagocytosis experiments carried out in the 
whole mouse may reflect a reduction in the phagocytic 
activity of only the macrophages fixed in situ, it was of 
concern to determine whether wandering macrophages were 
also impaired. In the following experiment, peritoneal 
exudate cells were harvested from normal mice and from mice 
which had been treated with the macrophage toxins. The 
cells were counted and evaluated for their ability to 
phagocytize heat-killed Candida stellatoideae cells.
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Fig. 6. Duration of RES suppression following treatment 
with carrageenan. Test mice received, a single i.p. injec­
tion of 5 mg carrageenan at time 0 and. were tested at various 
times for their ability to clear carbon from the peripheral 
blood. Normal mice received an equal volume of PBS, Each 
value represents the arithmetic mean of 5 mice.
Symbols :
Normal range of oC value
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Table I shows that 24- h after MUS or carrageenan treatment, 
the total number of macrophages harvested from the peri­
toneal cavity was lower than normal. Concurrent with 
enumeration, cells were also evaluated for viability by 
trypan blue exclusion, A lower percent of viable cells 
were obtained from MUS-treated and carrageenan-treated 
mice as compared with normal mice. The predominant cell 
type obtained from normal and MUS-treated mice were lymph­
ocytes, whereas, the predominant cell type in carrageenan- 
treated mice were polymorphonuclear cells (PMN), When 
macrophages from MUS-treated and carrageenan-treated mice 
were incubated with heat-killed Ç. stellatoideae. the 
yeast were phagocytized less effectively than by macro­
phages from control mice which had been injected with only 
PBS. Thus, not only were fewer viable macrophages ob­
tained from the mice treated with MUS and carrageenan but 
those that were obtained, had lessened phagocytic activity.
Distribution of radiolabeled LPS in normal and macronhage- 
impaired mice
The carbon clearance data demonstrated clearly that 
following the treatment of mice with MUS, there was a 
suppression in the ability of the RES to clear carbon 
particles from the peripheral blood. Similarly, the carbon- 
clearing ability of the RES in carrageenan-treated mice was
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II Table 1
C/)
o'3
The Effect of MUS and Carrageenan 
on Peritoneal Exudate Cells
CDO
CDQ.
"OCD
cn
C/)
Group Cells/ml Absolute Viability
ë'
i3CD
Lympho­
cytes
Macro­
phages
P o l y ­
morphs
#
Macro­
phages
cytic
Index
"ncp.3*CD Normal^ 1.2 X 10^ 55 43 2 5.2 X 10^ 96 77
S■o MUS® 1.3 X 10^ 63 3^ 3 4.4 X 10^ 85 54D.Cao
f
Normal 1.3 X 10^ 57 42 1 5.5 X 10^ 95 78
■DO3"CJ
Carrageenan^ 1.7 X 10^ 6 10 84 1.7 X 10^ 82 47
mice/group 
^Trypan Blue exclusion
^Percent of adherent cells (macrophages) containing at least 2 Candida stellatoidea. 
^PBS injected i.v.
®10 mg KUS injected i.v.
^PBS injected i.p.
-5 mg carrageenan injected i.p.
-p-o
4 l
impaired. Experiments were performed to determine if the 
clearance of an antigen was also affected. Therefore, LPS 
was radiolabeled with ^^Cr as described in the Materials 
and Methods section. The radioactive LPS (LPŜ )̂ was in­
jected i.v. into mice previously treated with the standard 
dose of MUS or carrageenan. Control mice received PBS by 
identical routes.
The ability to clear the LPŜ  ̂by mice exposed to 
either macrophage toxin was dramatically impaired (Table 2 
and 3). By 5 min following the i.v. injection of LPS"*̂  into 
normal mice, only about of the total injected concen­
tration could be recovered in whole blood. However, in 
mice treated previously with MUS prior to the i.v, in­
jection of LPS^, about k-0% of the antigen injected was 
present in whole blood. Similarly, carrageenan-treated 
mice retained about h-jfo of the injected LPS"’*' in the circu­
lating whole blood after 5 min. The concentration of LPŜ  ̂
within the circulating whole blood in all groups diminished 
with time. However, the rate of LPŜ  ̂clearance from the 
blood in mice exposed to MUS or carrageenan was less than 
the clearance rate in normal mice.
As seen in Table 2, LPŜ  ̂was quantified also in vari­
ous organs. Prior to counting, the individual organs were 
rinsed with PBS but were not perfused. Therefore, the 
counts in the organs obtained while the peripheral blood
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Table 2
Tissue Distribution 6f ^^Cr-labeled LPS in Normal and Macrophage-impaired Mice
C/)
C/)
83ci'
Nanograms of LPS
33"
CD
CD■DOQ.CaO3"OO
CDQ.
■D
CD
C/)
C/)
Group Organ
5 min.
Time 
30 min.
of Assay 
Ih 6h 24h 48h
Blood® 364 272 108 84 48 28
Spleen 78 56 41 42 54 46
Normal Liver 783? 7709 7690 7406 7434 7340Kidneys 65 45 36 37 31 32Lungs 27 29 9 7 13 7
Blood® 4068 3276 2880 1824 544 248
a Spleen 973 836 778 787 887 864MUS^ Liver 1644 1568 2180 2424 3196 3290Kidneys 207 216 238 189 118 119Lungs 174 3I8 77 44 75 63
Blood® 4324 3900 4164 ND^ ND ND
Spleen 223 206 204 I® ND NDCarrageenan® Liver 1278 1849 1760 ND ND ND
Kidneys 186 206 296 1® ND ND
Lungs 190 273 220 ND ND ND
r\5
®A11 mice received 10,000 ng of ^^Cr-labeled LPS l.v, at time 0,
■uNanograms of LPS were calculated by the following formula:
ng of LPS = (10,000 ng LPS) (counts/organ) / (100,394 counts/10,000 ng LPS]
All samples were counted for the same period of time and were corrected for back­
ground and decay. Each value represents the arithmetic mean of 3 mice/group,
®0,5 ml of blood was counted. Amount of LPS was calculated assuming a circulating 
blood volume of 2.0 ml
^Mice received 10 mg MUS i.v. at time -6 h.
®Mice received 5 mg carrageenan i.p, at time -6 h.
^N.D, Not done
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Table 3
Percent Tissue Distribution of ^^Cr-labeled LPS 
in Normal and Macropbage-impaired Mice
Organ Percent of Total Injected LPS
5 min.
Time 
30 min.
of Assay 
1 h 6 h 24 h 48 h
Blood® 3.6 2.7 1.1 0.8 0.5 0.3Spleen 0.8 0.6 0.4 0.4 0.5 0.5Normal Liver 78.4 77.1 76.9 74.1 74.3 73.4Kidneys 0.7 0.5 0.4 0.4 0.3 0.3Lungs 0.3 0.3 0.1 0.1 0.1 0.1
Blood® 40.7 32.8 28.9 18.2 5.4 2.5, Spleen 9.7 8.4 7.8 7.9 8.9 8.6m s ^  Liver 16.4 15.7 21.8 24.2 3 2 .0 32.9Kidneys 2.1 2.2 2.4 1.9 1.2 1.2Lungs 1.7 3.2 0.8 0.4 0.8 0.6
Blood® 43.2 39.0 41.6 KD^ ND ND
Spleen 2.3 2.1 2.0 ND ND NDCarrageenan Liver 12.8 18.5 17.6 ND ■ ND ND
Kidneys 1.9 2.1 3.0 ND ND ND
Lungs 1.9 2.7 2.2 ND ND ND
®A11 mice received 10,000 ng of 
^Percent of total Injected LPS ^
^^Cr-labeled LPS i.v. 
_ ng of LPS in organ 
ng of LPS injected
at time
X 100
0.
®0.5 ml of blood was counted. Percent of LPS was calculated assuming a circulating 
blood volume of 2.0 ml.
^Mice received 10 mg IfOS i.v. at time - 6 h.
®Mice received 5 mg carrageenan i.p. at time - 6 h,
^N.D, Not done.
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LPS* concentration was high, probably reflected some LPS* 
contained in the blood in addition to the specific 
localization of LPS* within these various organs. It can 
be seen that a relatively small amount of the total LPS* 
injected was found in the kidneys and lungs. However, the 
liver and spleen showed considerable localization of LPS*.
In normal control mice 78^ and 0.8^ of the total injected 
LPS* were found in the liver and spleen respectively, after 
5 min, MUS-treated mice revealed l6^ LPS* recovered from 
the liver while was recovered from the spleen. It was 
probable that the increased amount of LPS* seen within the 
spleen in MUS-treated mice represented an increased 
localization of LPS* and not merely entrapment of peripheral 
blood, since this value remained constant throughout the 
experiment and did not decrease proportionally with the 
amount of LPS* in the peripheral blood. Similarly, in 
carrageenan-treated mice, 13^ and 2% of the injected LPS* 
was recovered from the liver and spleen, respectively, 
after 5 min. Again it was assumed that the increase in 
splenic LPS* represented a true increased localization of 
LPS*, since the increased values persisted at this level 
throughout the duration of the experiment.
Localization of LPS* within the liver of treated mice 
increased with time throughout the experiment. After 48 h 
the amount of LPS* recovered from the liver of MUS-treated 
mice had increased to 33^ of that injected, while in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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carrageenan-treated mice approximately 20^ of the injected 
LPS* was localized in the liver. By comparison, normal 
mice retained of the injected LPS* at 48 h.
Thus, additional evidence was obtained which showed 
that MUS and carrageenan had impaired macrophages. The 
increase in splenic localization of LPS* was relatively 
greater than in other tissues in treated mice. Organs 
which were examined for localization of LPS* included 
stomach, intestines, bladder, mesenteric lymph nodes, 
inguinal lymph nodes, axillary lymph nodes and popliteal 
nodes. However, none of these appeared to be specific sites 
for localization of LPS* in either normal or treated mice. 
These data may be important in light of further observa­
tions presented in the next sessions.
Sensitivity of MUS and carrageenan-treated mice to LPS 
toxicity
It is well established that agents which either block­
ade or reduce RES function render animals more susceptible 
to the toxicity of LPS (37, 93). Based on this observa­
tion, the median lethal dose (LD^q ) to LPS should reflect 
the in vivo functional capacity of the RES, Mice were in­
jected with 10 mg MUS i.v, or with 5 mg carrageenan i.p. 
These injections were followed by the i.p, injection of 
varying amounts of LPS, Controls consisted of animals re­
ceiving only MUS or carrageenan but no LPS and normal mice
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receiving only the LPS. The mice were observed and deaths 
recorded at 12 h intervals until termination of the experi­
ment at 72 h.
Figure ? shows that mice receiving LPS concurrently 
with either MUS or carrageenan were more susceptible to the 
toxicity of LPS than were normal mice, MUS-treated mice
were approximately 40 times more sensitive to LPS toxicity
4than normal mice. An LD^^ value of 2.7 x 10 ng of LPS 
(Pig. 8) was obtained with TiUS-treated mice, whereas normal 
mice exhibited no deaths even at the highest dose of LPS 
(1 X 10^ ng). Carrageenan-treated mice were approximately
3,000 times more sensitive to LPS toxicity with an LD^^ 
value of 3.7 x 10^ ng of LPS. Hence, the LD^^ values 
obtained with MUS-treated and carrageenan-treated mice 
provided additional evidence that impairment of the EES had 
occurred.
Primary antibody responses of mice friven antigen at 
varying times dur in/? macronhage impairment
Other authors have presented data indicating that the 
time at which mice were challenged with antigen during the 
course of macrophage impairment was critical to the re­
sultant antibody response (52, 72, 81). Therefore, experi­
ments were designed to expose mice to antigen at varying 
intervals prior to and after the dose of macrophage toxins.
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Fig. 7. Sensitivity of MUS or carrageenan-treated mice to 
LPS toxicity. Mice were injected with 10 mg of MUS i.v, or 
5 mg of carrageenan i.p. at time 0, followed by the in­
jection of varying amounts of LPS i.p. Normal mice received 
PBS by identical routes followed by the injection of LPS
i.p.
Symbols :
 ......  Normal mice
Carrageenan-treated mice 
MUS-treated mice
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Mice were challenged with antigen as early as 24 h prior 
to the standard dose of MUS (carrageenan) or as late as 5 
days after the injection of macrophage toxin. Mice were 
bled 5 days after the dose of antigen and their sera were 
pooled and titrated for antibody.
As shown on Table 4, if either LPS or SRBC antigen was 
given prior to or concurrently with either macrophage toxin 
there was no observable difference in the resultant anti­
body titer as compared to normal mice. The only observable 
difference in titer between normal mice and mice injected 
with macrophage toxins occurred when mice were challenged 
with 0.2 ml of 0,03% SRBC suspension 6 h and 24 h after ex­
posure to either macrophage toxin. As seen on Table 4, mice
that received MUS or carrageenan demonstrated an enhanced 
antibody titer to the lower dose of SRBC, Mice that re­
ceived antigen later than 24 h after exposure to macro­
phage toxins did not demonstrate an observable difference 
in the antibody response.
It was found in this experiment that the only observa—  
ble difference in the antibody response occurred when mice 
received a sub-maximal SRBC antigenic challenge 6 h and 
24 h after exposure to MUS or carrageenan. However, at no 
time during RES suppression by either macrophage toxin was 
there a decrease in antibody response, regardless of the
time of exposure to the toxin.
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Table 4
Primary Antibody Responses of Mice Immunized at 
Varying Intervals During Macrophage Impairment
Antigen Antibody Titer
Time of Antigen Administration (hours)
-24 -6 0 6 24 48 72 96 120
10 ug LPS 7 8 8 7 7 8 7 7 8
0,1 ug LPS 5 5 6 4 5 5 4 5 5
10^ SRBC 7.5 8 7 8 7.5 8 8 7 7.5
0.05^ SRBC 4 4.5 5 4 4 4 4.5 4 5
10 ug LPS 7 8 8 7 6 7 7 6 6
10$ SRBC 7 8 8 7 7 7 7 8 7
0.05$ SRBC 5 5 5 6 6 4.5 5 5 4
0.1 ug LPS 6 4 5 5 5 4 6 4 6
10$ SRBC 7 7 8 7.5 7 7 8 8 7
0.05$ SRBC 4.5 4 4 6 6 4 3.5 4 4.5
^PBS, 10 mg MUS or 5 mg carrageenan injected at time 0 (5 mice/group).
^Mice were bled 5 days after antigenic challenge, sera pooled and titers determined,
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Kinetics of the -primary antibody response to LPS and SRBC 
in r-KJS-treated mice
The kinetics of the primary antibody response to LPS 
was evaluated in MUS-treated and normal mice. Animals 
received the standard dose of MUS and 6 h later were chal­
lenged i.v. with antigen. Control groups received an 
equal volume of PBS i.v, and were challenged similarly 
with antigen. Groups of 5 mice were bled daily, their sera 
pooled and evaluated for antibodies to LPS by passive hemag­
glutination. As shown in Fig. 8, there does not appear to 
be a difference in either the kinetics or in the magnitude 
of the resulting antibody response. With either dose of 
LPS (10 ug or 1 ug), initial antibody responses could be 
detected after 3 days. Maximum antibody titers in treated 
mice, as well as normal mice were obtained on day 5 and 
persisted at this level for the duration of the experiment.
Sera obtained on the fifth day were also treated with 
2-mercaptoethanol (2-ME) in order to estimate the relative 
amounts of antibody in the IgM and IgG classes. Serum 
samples were treated with 2-ME, as described in the 
Materials and Methods section, and then titrated for the 
presence of specific antibody activity. When the titers of 
the sera before and after treatment with 2-ME were compared 
it was possible to determine the relative contribution if 
IgM and IgG antibodies to the total response. Following
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Fig. 8, Kinetics of the primary antibody response of 
normal and MUS-treated mice to LPS. Mice were injected 
at time 0 with 10 mg MUS or PBS i.v. followed 6 h later 
with the injection of LPS. Mice were bled on 8 consecu­
tive days and titers were determined by passive hemag­
glutination, Each point represents the antibody titer 
of sera pooled from 5 mice/group.
Symbols :
-A A Normal mice
 MUS-treated mice
A. Mice injected with 10 ug LPS, i.v.
B. Mice injected with 1 ug LPS, i.v.
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treatment with 2-ME there was no residual antibody titer 
detectable by passive hemagglutination. Therefore, the 
antibody response for both groups of mice was primarily IgM.
Treated and normal mice were also evaluated for their 
ability to respond to the T-cell dependent SRBC antigen.
The experimental protocol was the same as that described 
previously for LPS, except that SRBC was used as the anti­
gen, With the high antigenic dose of SRBC (0.2 ml of 10^ 
SRBC) initial antibody responses could be detected 2 days 
after antigenic stimulation in both groups of mice.
(Fig, 9 A), After the second day the kinetics of the anti­
body response were similar for both groups until approxi­
mately the seventh day. At that time the MUS-treated mice 
attained a peak titer of 11, while the normal mice peaked 
at a titer of 8.5. When mice were challenged with the sub- 
maximal dose of SRBC (0.2 ml of 0.05^ SRBC) both the kinet­
ics and magnitude of the antibody response varied. Circu­
lating antibodies to SRBC could be detected in macrophage- 
impaired mice at 2 days, but were not detectable in normal 
mice until 4 days after antigenic stimulation (Pig. 9 B).
Mot only were circulating antibodies demonstrable earlier 
in macrophage-impaired mice, but the maximum antibody 
response was 4 fold (end point dilution of 192 vs 48) higher 
than the maximum antibody response generated by normal mice.
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Fig, 9. Kinetics of the primary antibody response of 
normal and MUS-treated mice to SRBC, Mice were injected 
at time 0 with 10 mg MUS or PBS i,v. followed,6 h later by 
the injection of SRBC, Mice were bled on 8 consecutive 
days and titers were determined by hemagglutination. Each 
point represents the antibody titer of sera pooled from 
5 mice/group.
Symbols ;
A ^ Normal mice
MUS-treated mice
A. Mice injected with 0,2 ml of 10^ SRBC, i,v.
B. Mice injected with 0,2 ml of 0,05^ SRBC, i.v.
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Kinetics of the primary antibody response to LPS and SRBC 
in carrageenan-treated mice
The kinetics of the primary antibody response to LPS 
was evaluated in carrageenan-treated and in normal mice. 
Mice were injected with the standard dose of carrageenan or 
PBS and 6 h later were injected i.v. with antigen. Because 
of the increased susceptibility to LPS in the carrageenan- 
treated mice, only one dose of LPS (0.1 ug) was used. As 
shown in Fig. 10, there was not any difference in either 
the kinetics or in the magnitude of the antibody response 
between macrophage-impaired and normal mice. Initial anti­
body responses could be detected in both groups, 3 days 
after the injection of antigen. Peak titers for both 
groups were reached on day 5 and titers tended to persist 
at this level for the duration of the experiment.
The primary antibody response of carrageenan-treated 
mice to SRBC was evaluated in a manner similar to that 
described above. Mice received the standard dose of carra­
geenan or PBS followed 6 h later by the i.v. injection of 
SRBC. With the larger dose of SRBC (0,2 ml of 10^ SRBC), 
both the time of development and magnitude of the resulting 
antibody titers were similar in both carrageenan-treated 
and normal mice (Pig, 11 A). Initial antibody responses 
were demonstrable 2 days after antigenic challenge. Peak 
titers in both groups were achieved 5 days after antigenic
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Pig. 10, Kinetics of the primary antibody response of 
normal and carrageenan-treated mice to LPS. Mice were 
injected at time 0 with PBS or 5 mg carrageenan i.p. 
followed 6 h later by the injection of LPS. Mice were 
bled on 8 consecutive days and titers were determined by 
passive hemagglutination. Each point represents the 
antibody titer of sera pooled from 5 mice/group.
Symbols :
Normal mice, injected i.v, with 0.1 ug of LPS
Carrageenan-treated mice, injected with 0.1 ug 
of LPS
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Pig, 11. Kinetics of the primary antibody response of 
normal and carrageenan-treated mice to SRBC, Mice were 
injected at time 0 with PBS or 5 mg carrageenan i,p, 
followed 6 h later by the injection of SRBC, Mice were 
bled on 8 consecutive days and titers were determined by 
hemagglutination. Each point represents the antibody 
titer of sera pooled from 5 mice/group.
Symbols :
-'A Normal mice
# Carrageenan-treated mice
A, Mice injected i.v, with 0,2 ml of 10^ SRBC,
B, Mice injected i.v, with 0,2 ml of 0,05/̂  SRBC,
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challenge and tended to persist at this level for the dura­
tion of the experiment. When mice received the sub-maximal 
dose of SRBC (0,2 ml of 0.05^ SRBC) both the kinetics and 
the magnitude of the antibody response were altered 
(Fig. 11 B). Initial antibody responses were detectable 1 
day earlier in carrageenan-treated mice than in normal mice. 
Maximum anti-SRBC titers were obtained 5 days after the in­
jection of antigen in both groups, however, there was an 
approximate 5 fold (end point dilution of 256 vs 48) in­
crease in the magnitude of the antibody response of the 
carrageenan-treated mice.
Primary antibody responses of normal and macrophage- 
immired mice to various concentrations of SRBC
During the characterization of the kinetics of the pri­
mary antibody response to the SRBC antigen, it was observed 
that MUS-treated or carrageenan-treated mice demonstrated 
higher antibody titers in their sera than normal mice. 
Further experiments were performed to determine if the en­
hanced primary antibody response to SRBC was dose dependent.
Groups of 5 mice were treated with the standard dose 
of MUS or carrageenan. Control groups received an equal 
volume of PBS by identical routes of injection. After 6 h, 
mice were injected with varying amounts of SRBC. Five days 
after the dose of antigen, the mice were bled, their sera
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pooled and titrated.
Figures 12 and 13 demonstrate that as the dose of 
SRBC was decreased, the resulting antibody titer decreased 
but still remained at an enhanced level in the MUS-treated 
and carrageenan-treated mice when compared to normal mice. 
In contrast, normal mice exhibited a more profound drop in 
the resultant antibody titer as the dose of antigen was 
decreased. Anti-SRBC titers of 7.5» 6 and 4 were obtained 
with 0.2 ml of 10^, 1% and 0.05^ SRBC, respectively, in 
normal mice, MUS-treated mice demonstrated anti-SRBC 
titers of 9.5» 8 and 7 to similar doses of antigen. Anti­
body titers of 7, 7 and 6.5 were obtained respectively in 
carrageenan-treated mice. Thus, the primary antibody re­
sponse to the SRBC antigen were consistently higher in mice 
previously treated with MUS or carrageenan.
The sera from both normal and macrophage-impaired mice 
were treated with 2-ME, As shown in Figs. 12 and 13» all 
mice receiving the primary antigenic challenge dose of
0.2 ml of 10% SRBC, possessed 2-ME resistant antibody 
activity. Normal mice exhibited a 12 fold (end point 
dilution of 384 vs 32) reduction in hemagglutinating 
activity following treatment of the sera with 2-ME, whereas 
MUS-treated mice showed only a 6 fold (end point dilution 
of 1536 vs 256) reduction in hemagglutinating activity. 
Similarly, carrageenan-treated mice showed an 8 fold (end
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Pig. 12. Primary antibody responses of normal and MUS 
treated mice to varying doses of SRBC, Mice were injected 
at time 0 with PBS or 10 mg of MUS i.v, followed 6 h later 
with the i.v. injection of SRBC. Mice were bled 5 days 
later and titers were determined by hemagglutination. Each 
value represents the antibody titer of sera pooled from 
5 mice/group.
Symbols :
Antibody titer of sera
I — I Antibody titer of sera following treatment
with 2-mercaptoethanol
A. Normal mice
B, MUS-treated mice
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Fig. 13. Primary antibody response of normal and 
carrageenan-treated mice to varying doses of SRBC, Mice 
were injected at time 0 with PBS or 5 mg of carrageenan
t
i.p. followed 6 h later with the i.v, injection of SRBC, 
Mice were bled 5 days later and titers were determined by 
hemagglutination. Each value represents the antibody titer 
of sera pooled from 5 mice/group.
Symbols :
Antibody titer of sera
^ Antibody titer of sera following treatment 
with 2-mercaptoethanol
A, Normal mice
B. Carrageenan-treated mice
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point dilution of 25é vs 32) reduction in titer following 
treatment of sera with 2-ME. Thus, the sera of mice 
immunized during macrophage impairment contained more IgG 
than did the sera of normal mice,
MUS or carrageenan-treated mice were also capable of 
generating a 2-ME resistant antibody response to an anti­
genic challenge dose of 0.2 ml of 1^ SRBC. Mice immunized 
during macrophage impairment with MUS or carrageenan demon­
strated a 16 to 8 fold (end point dilution of 512 vs 32 and 
256 vs 32) reduction in the total antibody titer following 
2-ME treatment, respectively. Conversely, in normal mice 
immunized with this dose of SRBC no 2-ME resistant anti­
bodies were found. When the antigen concentration was re­
duced to a 0.05/̂  SRBC suspension no 2-ME resistant activity 
was present in either the macrophage impaired or control 
group.
Thus, when the higher dose of SRBC (0.2 ml of 10^
SRBC) was employed, the resulting antibody response in both 
normal and treated animals was a mixture of IgG and IgM 
antibodies. Conversely, with a lower dose of SRBC (0.2 ml 
of 0.05^) only IgM antibodies were generated in both nor­
mal and treated animals. At the intermediate SRBC dose, 
specific antibodies of IgM and IgG classes were generated 
only in the mice exposed to macrophage toxins prior to 
antigenic challenge, while normal control mice responded
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with antibody production in only the IgM class.
Release of Hemopclobin following: exposure of SRBC to MUS 
or carrap:eenan
Feldmann and co-workers (27, 28) had shown previously 
that the production of an antibody response to SRBC in vitro 
was dependent upon three cell types; T-lymphocytes, 
B-lymphocytes and macrophages. They were also able to 
demonstrate, with in vitro experiments, that macrophages 
were required only when intact SRBC were used as antigens.
If the SRBC were sonicated and presented to only the T cells 
and B cells in the soluble form, it was noted that antibody 
production would occur without the presence of macrophages. 
Thus, it appeared that the soluble form of the SRBC antigen 
was macrophage independent in vitro, whereas the intact 
SRBC antigen was macrophage dependent.
Since primary antibody responses to SRBC in macrophage- 
impaired mice were equal to or greater than the antibody 
response of normal mice, it was of importance to determine 
if this enhancement possibly was due to a lytic action of 
MUS or carrageenan on the SRBC in vivo. If this was 
occurring the role of the macrophage as a possible anti- 
gen-processing cell would be circumvented. Therefore, MUS 
and carrageenan were analyzed in vitro for their ability 
to lyse SRBC.
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As shown in Table 5i there was no difference in the 
free hemoglobin levels between control sera and sera plus 
in vivo concentrations of MUS or carrageenan. If either 
macrophage toxin were capable of inducing lysis of the 
SRBC, this should have been reflected in a higher free 
hemoglobin level. Since this was not observed with either 
MUS or carrageenan, it could be surmised that the in vivo 
amounts of macrophage toxins employed in the present 
study were not lytic to SRBC.
Passive transfer of sera from normal and macrophage- 
impaired mice into normal mice which received LFS or SRBC
The destruction of macrophages in vivo by MUS or 
carrageenan should result in the release of intracellular 
enzymes into the peripheral blood. Measurement of these 
enzymes would offer a method for determining the extent of 
macrophage destruction that had occurred. Therefore, 
experiments were designed to assay the sera from mice re­
ceiving MUS or carrageenan for acid phosphatase and lactate 
dehydrogenase (LDH) levels. These same sera were then 
transferred passively into normal mice, which subsequently 
were challenged with antigen and their antibody titers 
determined.
Mice were treated with the standard dose of MUS or 
carrageenan. Control mice received an equal volume of 
PBS by identical routes of injection. The mice were
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Table 5
Release of Hemoj^lobin Following Exposure of 
SRBC to MRS or Carrageenan
Free
Group Incubation Mixture
A B C
Controls serum serum serum 12
serum serum SRBC 12
serum PBS SRBC 12
serum water SRBC 20
water water SRBC 520
MUS serum MUS SRBC 11
Carra­
geenan
serum Carra­
geenan
SRBC 12
A. 1 ml of serum or water.
B. 0.2 ml of serum, PBS, water MUS or carrageenan.
C, 0.2 ml of serum or 10^ SRBC
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sacrificed 24 h after the exposure to macrophage toxins 
and were bled by axillary incision. Blood was collected 
in chilled tubes, refrigerated for 1 h at 4°C and the sera 
removed. Enzymatic assays as described in the Materials 
and Methods section were performed immediately on the fresh 
harvested sera. Normal mice then received 1,0 ml of the 
appropriate sera i,p, followed immediately by the i.p, 
injection of LPS or SRBC, Mice were bled 5 days later and 
serum antibody titers determined. The i.p, route of in­
jection of both sera and antigen was chosen to avoid cir­
culatory overload and to allow intimate contact in vivo 
between antigen and the enzymatically active sera.
As shown in Table 6, the serum levels of acid phos­
phatase and LDH activity in mice receiving either macro­
phage toxin were higher than in control mice. The acid 
phosphatase values in treated mice were 2-3 times normal 
while LDH values showed a 12-15 fold increase. The release 
of acid phosphatase from the lysosomes of phagocytic cells 
occurs not only as the direct result of cell death, but 
can be triggered by phagocytosis or after contact with 
antigen-antibody complexes. However, the cytoplasmic 
enzyme, LDH, is not secreted or released unless the cell 
has been destroyed (91). Therefore, measurement of LDH 
gives a better indication of the amount of cell destruction 
that has occurred in vivo.
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Table 6
Serum Enzyme Levels of Normal and 
Macrophage-impaired Mice®'
Group Acid
Phosphatase (lU/L)
Lactate 
Dehydrogenase (lU/L)
Normal^ 0.53 148
MUS° 1.08 I860
Normal^ 0.50 166
Carrageenan® 1.56 2506
®Enzymatic assays were performed 24 h after the mice were 
injected with either PBS, MUS or carrageenan. Each 
value represents the enzymatic activity of the sera 
pooled from 50 mice.
^Mice were injected i.v. with PBS.
®Mice were injected i.v. with 10 mg MUS.
^Mice were injected i.p. with PBS.
®Mice were injected i.p. with 5 mg carrageenan
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Figures l4, 15 and l6 show the anti-LPS and anti-SRBC 
titers of mice receiving normal or treated sera with 
standard doses of antigen. No observable differences were 
seen in the antibody titers between recipients of either 
type of serum in any of the groups. Although enzymatic 
analyses showed macrophage autolysis and release of intra­
cellular enzymes, the increased enzymatic activity and/or 
the release of soluble factors from damaged macrophages 
did not affect the in vivo antigenicity of either LPS or 
SRBC.
Secondary response of normal and macrophage-impaired mice 
to LPS
It was shown previously that MUS or carrageenan- 
treated mice responded with a primary humoral antibody 
response equally as well or better than normal mice to 
the T-cell independent LPS antigen. It was of interest 
to determine if a secondary antibody response could be 
induced as efficiently in mice receiving the primary anti­
genic dose during macrophage impairment as in normal mice.
Mice were treated with the standard dose of MUS or 
carrageenan and 6 h later received the priming dose of 
LPS (1,0 ug or 0,1 ug) i,V, A standard secondary dose of 
LPS (1,0 ug) was administered 21 days later. Control mice 
received an equal volume of PBS by identical routes of
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Fig. 14. Primary antibody responses of mice to a 1.0 ug 
dose of LPS given after receiving sera from normal and 
macrophage-impaired mice. Mice were injected at time 0 
with PBS, normal mouse sera or macrophage impaired mouse 
sera i.p. followed immediately by the injection of 1.0 ug 
of LPS i.p. Mice were bled 5 days later and titers were 
determined by passive hemagglutination. Each value 
represents the antibody titer of sera pooled from 5 mice/ 
group.
^Mice received only antigen.
^Mice received antigen and 1.0 ml PBS.
°Mice received antigen and 1.0 ml of sera obtained 
from mice treated with PBS 24 h earlier.
^Mice received antigen and 1.0 ml of sera obtained
from mice treated with 10.0 mg of MUS 24 h earlier.
®Mice received antigen and 1.0 ml of sera obtained 
from mice treated with 5 mg of carrageenan 
24 h earlier.
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Pig. 15. Primary antibody responses of mice to.0,2 ml of 
0.05% SRBC after receiving sera from normal and macrophage- 
impaired mice. Mice were injected at time 0 with PBS, 
normal mouse sera or macrophage-impaired mouse sera i,p. 
followed immediately by the injection of 0,2 ml of 0,05^ 
SRBC i.p. Mice were bled 5 days later and titers were 
determined by hemagglutination. Each value represents the 
antibody titer of sera pooled from 5 mice/group.
^Mice received only antigen.
^Mice received antigen and 1.0 ml PBS.
^Mice received antigen and 1.0 ml of sera obtained 
from mice treated with PBS 24- h earlier,
^Mice received antigen and 1,0 ml of sera obtained
from mice treated with 10.0 mg of MUS 24 h earlier,
®Mice received antigen and 1,0 ml of sera obtained 
from mice treated with 5 mg of carrageenan 
24 h earlier.
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Fig. 16. Primary antibody responses of mice to 0,2 ml
of 10% SRBC after receiving sera from normal and
macrophage-impaired mice. Mice were injected at time 0 
with PBS, normal mouse sera or macrophage-impaired mouse 
sera i.p. followed immediately by the injection of 0,2 ml 
of 10% SRBC i.p. Mice were bled 5 days later and titers 
were determined by hemagglutination. Each value 
represents the antibody titer of sera pooled from 
5 mice/group.
^Mice received only antigen.
^Mice received antigen and 1.0 ml PBS.
°Mice received antigen and 1.0 ml of sera obtained
from mice treated with PBS 24 h earlier,
^Mice received antigen and 1.0 ml of sera obtained 
from mice treated with 10,0 mg of MUS 24 h 
earlier.
®Mice received antigen and 1.0 ml of sera obtained 
from mice treated with 5 mg of carrageenan 
24 h earlier.
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injection. Additional controls included mice receiving 
only the primary or secondary dose of antigen. All mice 
were bled 4 days after receiving the secondary antigen and 
their sera were pooled and titered.
As seen on Tables 7, 8, 9 and 10, there was no dif­
ference in the ability to elicit a secondary antibody 
response in mice primed with antigen during macrophage 
impairment as compared with normal mice. The magnitude of 
the secondary responses to both doses of priming antigens 
were equal in macrophage-impaired and normal mice. No 
residual antibody titer was detected following treatment of 
the sera with 2-ME, thus indicating that the secondary 
response generated in both treated and normal mice was pre­
dominately an IgM antibody response.
Of most interest, however, were the results generated 
within the control groups. The anti-LPS titers were con­
siderably higher in mice treated with macrophage toxins 
and given no primary dose of LPS prior to the secondary in­
jection of antigen than in normal mice. The antibody 
responses generated in the macrophage-impaired group ap­
proached the magnitude of the secondary antibody responses 
of normal mice which received two doses of LPS, Qualita­
tively, these antibodies to LPS were demonstrated to be of 
the IgM type. Thus, mice only exposed to either MUS or 
carrageenan 21 days earlier responded to the single dose of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 7
Secondary Antibody Responses of Normal and MUS-treated
Mice Primed with 1.0 ug LPS
Group Treatment^
Primary , 
Injection 
(Day 0)
Secondary 
Injection 
(Day 21) Total
Antibody Titer^
(Day 25) _
2-ME Resistant
A PBS LPS LPS 11.5 0B MUS LPS LPS 11.5 0
C PBS None LPS 6.5 0D MUS None LPS 10 0
E PBS LPS None 4- 0
F MUS LPS None 5 0
CDK)
^Hice were treated at time 0 with 10 mg NUS or PBS i.v.
^Kice received 1.0 ug of LPS i.v. 6 h after treatment.
^Mice received 1,0 ug of LPS i.p.
^Sach value represents the antibody titer of sera pooled from 5 mice/group.
®Each value represents the antibody titer of sera pooled from 5 mice/group after
treatment with 2-ME.
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Table 8
Secondary Antibody Responses of Normal and MUS-treated Mice
Primed with 0.1 ug LPS
85
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Group Treatmenta
Primary , 
Injection 
(Day 0)
Secondary 
Injection 
(Day 21} Total
Antibody Titer 
(Day 25)
2-ME Resistant®
3.
3"
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CD"DO
Q .Cao
3"DO
CDQ.
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3
A PBS LPS LPS 11 0
B T'TUS LPS LPS 11.5 0
C PBS None LPS 4 0
D MUS None LPS 12 0
.E PBS LPS None 1 0
P MUS LPS None 4 0
COw
^Mice were treated at time 0 with 10 mg of MUS or PBS i.v,
^Mice received 0.1 ug LPS i.v. 6 h after treatment.
^Mice received 1.0 ug of LPS i.p.
‘̂Each value represents the antibody titer of sera pooled from 5 mice/group.
®Each value represents the antibody titer of sera pooled from 5 mice/group after
treatment with 2-ME.
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Table 9
Secondary Antibody Responses of Normal and Carrageenan-treated
Mice Primed with 1.0 ug LPS
Group Treatment^
Primary . 
Injection 
(Day 0)
Secondary 
Injection 
(Day 21)
Antibody Titer^
(Day 25) _ .
Total 2-NE Resistant®
A PBS LPS LPS 10 0
B Carrageenan LPS LPS 11 0
C PBS None LPS 5.5 0D Carrageenan None LPS 10 0
E . PBS LPS None 4 0
P Carrageenan LPS None 3 0
P̂ilce
^Mice
were treated at time 0 with 5 mg Carrageenan or PBS 
received 1.0 ug of LPS i.v. 6 h after treatment.
i.p.
CO
4T
^Mice received 1.0 ug of LPS i.p.
‘̂Each value represents the antibody titer of sera pooled from 5 mice/group.
®Eaoh value represents the antibody titer of sera pooled from 5 mice/group after
treatment with 2-Iffi.
■oo
û .cgQ. Table 10
"O
CD
C/îWo"3O
Secondary Antibody Responses of Normal and Carrageenan-treated
Mice Primed with 0,1 ug LPS
8
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CD
Groun Treatment"
Primary , 
Injection 
(Day 0)
Secondary 
Injection 
(Day 21) Total
Antibody Titer 
(Day 25)
2-ME Eesistant®
3.
3"
CD
CD
" DO
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3TDO
&
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CD
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3
A PBS LPS LPS 9 0B Carrageenan LPS LPS 10 0
C PBS None LPS 6 0
D Carrageenan None LPS 9.5 0
E PBS LPS None 0 0
F Carrageenan LPS None 2 0
Viice received 0.1 ug of LPS i.v. 6 h after treatment.
Mice received 1.0 ug of LPS i.p.
A 'Each value represents the antibody titer of sera pooled from 5 mice/group.
®Each value represents the antibody titer of sera pooled from 5 mice/group after
treatment with 2-ME.
CO
Mice were treated at time 0 with 5 mg Carrageenan or PBS i.p.
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LPS in a manner* similar to normal mice receiving both 
primary and secondary doses of antigen. In summary, then, 
it was shown that the antibody responses generated in mice 
receiving antigen 21 days after exposure to MUS or 
carrageenan, resembled a secondary antibody response.
Due to the consistent finding that secondary-type 
antibody responses could be elicited by a single dose of 
antigen in mice exposed to macrophage toxins 21 days prior 
to immunization, it was of interest to examine the spleens 
of these animals in order to determine the number of 
specific antibody forming cells. Groups of mice were 
treated with either MUS or carrageenan and after 21 days 
received a single injection of LPS, Five days after immu­
nization the spleens were removed, single cell suspensions 
were prepared, and the number of direct plaque forming 
cells (PPG) determined as described in Materials and 
Methods. Blood samples were also collected from these 
mice and were tested for hemagglutinating antibody titers.
In normal mice which received both a primary and 
secondary antigenic dose, the number of direct PPG/spleen 
was about 25 times higher than that of normal mice which 
received only one immunizing dose of LPS (Table 11), 
Therefore, normal mice were primed to LPS with the primary 
injection of antigen, and a specific population of anti- 
LPS memory cells generated. These observations were also 
reflected in the antibody titers. Normal mice which
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Table 11
Antibody Responses of Normal and Macrophage-impaired Mice to LPS
Group Treatment^
Primary , 
Injection 
(Day 0)
Secondary 
Injection 
(Day 21)
Antibody Titer^
-.(Day 25) _ 
Total 2-ME Resistant
PFC/Spleen^ 
(Day 25)
A PBS (i.v.) LPS LPS 10 0 13,860
B PBS (i.p.) LPS LPS 10.5 0 13,275C PBS (i.v.) None LPS ^.5 0 495D MUS None LPS 9.5 0 5,400S PBS (i.p.) None LPS 5.0 0 526
F Carrageenan None LPS 10.5 0 4,950
G PBS (i.v.) None None 0 0 14
H MUS None None 0 0 28
I PBS (i.p.) None None 0 0 23J Carrageenan None None 0 0 27
^Mice were treated at time 0 with either 10 mg I'GJS i.v. or 5 mg carrageenan i.p.
Control mice received an equal volume of PBS by identical routes of injection.
^Mice received 1.0 ug of LPS i.v. 6 h after treatment.
^Mice received 1.0 ug of LPS i.p.
*̂ Each value represents the antibody titer of sera pooled from 5 mice/group.
®Each value represents the antibody titer of sera pooled from 5 mice/group after 
treatment with 2-ME
^Spleens from mice of each group were pooled and tested for direct plaque-forming
cells (PEG).
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received only a primary antigenic dose, developed cir­
culating antibody titers of 4.5, whereas, normal mice 
which received both a primary and secondary antigenic dose 
developed titers of 10.5.
The number of direct PFC/spleen found in mice treated 
with either MUS or carrageenan 21 days prior to re­
ceiving the only injection of LPS was approximately ID 
times that of normal mice receiving only one injection of 
antigen. Titers of the circulating antibody level revealed 
that mice treated with macrophage toxins 21 days prior to 
the primary injection of antigen developed antibody titers 
that were over 50 fold higher than those observed in nor­
mal mice which received only one dose of antigen. Thus, the 
increased level of circulating antibodies within the mice 
exposed to macrophage toxins was equivalent to the anti­
body levels found in normal mice, which had received both 
a primary and secondary injection of LPS. It is of interest 
that the circulating antibody titers were equivalent, but 
the number of direct PPC/spleen was approximately three 
times lower in macrophage impaired mice than in normal 
mice. Approximately 13,000 direct PFC/spleen were found 
in normal mice during the typical secondary antibody re­
sponse, whereas, only about 5,000 direct PFC/spleen were 
found in the macrophage-impaired mice during the secondary-, 
type antibody response. Thus, it appears that either the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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rate of antibody synthesis is increased in mice previously 
exposed to macrophage toxins or else a major amount of 
antibody production has occurred in other lymphoid organs.
Secondary antibody response of normal and macrophage- 
impaired mice to SRBC
Due to the difficulty in eliciting an IgG type 
secondary antibody response to the LPS antigen, it was of 
interest to determine what type of secondary response would 
be elicited to the SRBC antigen. Experimental protocol was 
identical to the secondary antibody response studies of 
LPS, except that mice received a primary immunizing dose of 
0.2 ml of a 10^ SRBC suspension i.v. followed 21 days later 
with the secondary immunizing dose of 0.2 ml of 10% SRBC 
suspension i.p.
Mice which received the primary SRBC antigenic dose 
during macrophage impairment were capable of eliciting a 
secondary antibody response to SRBC. This response was both 
quantitatively and qualitatively equal to the secondary 
antibody responses of normal mice (Table 12). Only anti­
bodies that were resistant to 2-ME were detectable in all 
the groups of mice tested, indicating that antibodies of 
the IgG type predominated. Therefore, the capability of 
the immune system to prime for a secondary antibody re­
sponse to the SRBC antigen was not impeded in mice exposed
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Table 12
Secondary Antibody Responses of Normal and Macrophage-impaired Mice to SRBC
Group Treatment^
Primary , 
Injection 
(Day 0)
Secondary 
Injection^ 
(Day 21)
Antibody Titer‘d 
(Day 29)
Total 2-ME Resistant®
A PBS (i.v.) SRBC SRBC 11.5 11.5B MUS SRBC SRBC 11 11
C PBS (i.p.) SRBC SRBC 11 11
D Carrageenan SRBC SRBC 10.5 10.5
E PBS (i.v.) None SRBC 6 3F MUS None SRBC 8 0
G PBS (i.p.) None SRBC 5.5 3H Carrageenan None SRBC 7 0
I PBS (i.v.) SRBC None 8.5 8.5
J. MUS SRBC None 9 6
K PBS (i.p.) SRBC None 8 8
L Carrageenan SRBC None 8 6
VOo
^Mice were treated at time 0 with either 10 mg MUS i.v. or 5 mg carrageenan i.p. 
Control mice received an equal volume of PBS by identical routes of injection.
^Mice received 0.2 ml of a 10̂  SRBC suspension i.v. 6 h after treatment.
^Mice received 0.2 ml of a 10^ SRBC suspension i.p.
*̂ Each value represents the antibody titer of sera pooled from 5 mice/group.
®Each value represents the antibody titer of sera pooled from 5 mice/group after
treatment with 2-ME.
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to macrophage toxins prior to receiving the primary anti­
genic dose.
Both control and treated mice possessed residual anti­
bodies to SRBC 25 days after receiving only the primary 
immunizing dose. Within the control mice these antibodies 
were determined by 2-ME resistance to be of the IgG type. 
Although the predominant antibody detectable within the 
macrophage-impaired mice was also IgG there were, in 
addition, 2-ME sensitive antibodies indicating that the 
production of IgM antibodies were prolonged in the macro­
phage -impaired groups.
The primary antibody responses in mice which received 
antigen 21 days after exposure to either macrophage toxin 
were of considerable interest. Normal mice responded 
to the primary immunizing dose of SRBC with both IgM and IgG 
antibodies in approximately equal proportions. Mice which 
were exposed to a single dose of either MUS or carrageenan, 
21 days prior to immunization with SRBC, while making 
quantitatively a primary level response, produced only an 
antibody response of the IgM type.
In summary, mice exposed to macrophage toxins prior to 
receiving a primary dose of SRBC were as capable as nor­
mal mice in the capacity to prime for a secondary antibody 
response to 0.2 ml of a 10^ SRBC suspension. Residual 
antibody titers 25 days after exposure to antigen were found 
to be only IgG in normal mice, whereas macrophage-impaired
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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mice still possessed some IgM as well as IgG type anti­
bodies. If a single dose of SRBC was given 21 days 
following exposure to either MUS or carrageenan, only an 
IgM antibody response was induced, whereas normal mice 
responded with both IgM and IgG immunoglobulins under 
similar conditions.
Secondary antibody responses of normal and macrophage- 
impaired mice to varying priming doses of SRBC
Further experiments were performed to determine if 
mice treated with macrophage toxins were as efficient as 
normal mice in their ability to prime for secondary anti­
body responses with smaller amounts of SRBC than were 
tested previously. As seen in Table 13, both mice treated 
with macrophage toxins and normal mice were primed to 
similar degrees at all doses of SRBC antigen tested.
Typical secondary antibody responses, indicated by a higher 
titer and/or IgG type antibody, were elicited in both 
groups given the secondary injection of antigen.
Residual primary antibody titers were detectable only 
within the groups of mice receiving a primary immunizing 
dose of 0.2 ml of 0.01% SRBC. These residual antibodies 
were found to consist of both 2-ME sensitive and 2-ME 
resistant types in mice receiving either MUS or carrageenan. 
Normal mice not only had a lower concentration of residual 
antibodies 25 days after immunization, but the hemaggluti-
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 13
Secondary Antibody fieaponscs of forti.al and Kacrophare-imp,aired Mice to 
Variouc Priminp: Doses of SRBC
Group Treatment
Primary Secondary Antibody Titer
(Day 0) (Day 21) Total 2 -ME Resistant®
1 PBS (I.v.) SRBC 0.01%) SRBC 7 5.52 MUS SH3C 0.01%) SHBC 10 7
3 PBS (i.p.) SR3C 0.01%) SRBC 7.5 64 Carr.a Keenan SR3C 0.01%) SRBC 9 7
5 PBS (I.v.) SRBC 0.01%) None 3 0
6 Kl!S SR.IC 0.01%) None 5 3
? PBS (i.p.) SREC 0.01%) None 2 08 Carrageenan SRcC 0.01%) Hone 6 4
9 PBS (i.v.) SRBC 0.001%) SRBC 7 • 5
10 MUS SRBC 0.001%) SRBC 7 5
11 PBS (i.p.) SRBC 0.001%) SHBC 8 5
12 Carrageenan SRBC 0.001%) SRBC 7.5 5
13 PBS (i.v.) SRBC 0.001%) None 0 014 MUS SRBC 0.001%) Hone 0 0
15 PBS (i.p.) SRBC 0.001%) None 0 016 Carrageenan SRBC 0.001%) None 1 0
17 PBS (i.v.) SRBC 0.0001%) SRBC 6.5 3
18 WJS SRBC 0.0001%) SRBC 6 4
19 PBS (i.p.) SRBC 0.0001%) SRBC 7 4
20 Carrageenan SREC 0.0001%) SRBC 7 4
21 PES (i.v.) SRRC 0.0001%) Hone 0 0
22 MI'S SRBC 0.0001%) Hone 0 0
23 PBS (i.p.) SRBC 0.0001%) Hone 0 024 Carrageenan SRRC 0.0001%) Hone 0 0
25 PES (i.v.) Hone SRBC 5 0
26 MTS [.one SRBC 6 0
27 PBS (i.p.) None SRBC 5 028 Carrareenan None SRBC 6 0
^Kice were treated at time 0 with either 10 mg MUS I.v. or 5 mg carrageenan i.p.
Control mice received an equal volume of PBS by Identical routes of injection.
^Mice received 0.2 .nl of the indicated SRBC suspens Ions i.v.
°Mice received 0,2 ml of a 0.05SÎ SRBC suspension I.p.
‘̂ Each value represents the antibody titer of sera pooled from 5 mice/group.
"^Rncb value reprerent.s the antibody titer of sera pooled from 5 inice/rroup after
treatment with 2-F.E.
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nation properties were destroyed after 2-ME treatment, 
indicating that these were I^M antibodies. Therefore, mice 
which had received the primary immunizing dose of SRBC 
during macrophage impairment maintained a higher concen­
tration of residual antibodies as well as antibodies of 
both the IgG and IgM classes.
Thus, priming for secondary antibody responses to the 
particulate SRBC antigen was not suppressed if mice re­
ceived priming doses of antigen during impairment of macro­
phage phagocytosis. Interestingly, if mice were immunized 
(0,2 ml of 0.01^ SRBC) during macrophage impairment both 
IgG and IgM classes of antibodies persisted 25 days later. 
However, in normal mice only IgM antibodies were present. 
Thus, the quantity and quality of antibody remaining in 
circulation 25 days after a primary injection of antigen 
appeared to be dependent upon the dose of antigen and the 
number of functional macrophages at the time of immuni­
zation. More antibody in total and especially more of the 
IgG class was produced and maintained in mice which had been 
injected with MUS or carrageenan.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER IV 
DISCUSSION
In recent years there have been several hypotheses 
concerning the possible role of macrophages in the in­
duction of humoral antibody responses. Derived from these 
hypotheses were suggestions that macrophages caused effects 
ranging from complete abrogation to an acceleration of the 
antibody response (25, 27, 47, 83). In the present study, 
the role of the macrophage in humoral immunity was evalu­
ated in vivo. This was done by testing the immune response 
of mice in which macrophages had been impaired by macro­
phage toxins. Mice which received the macrophage toxins 
prior to immunization were still capable of producing nor­
mal to supranormal humoral antibody responses to T-cell 
independent (LPS) and T-cell dependent (SRBC) antigens. 
However, when the primary antibody response to the T-cell 
dependent antigen was compared between normal and macro­
phage -impaired mice, a relationship was observed which was 
dependent on the dose of antigen. This relationship 
appeared to affect not only the kinetics and magnitude of 
the antibody response but also the class of antibody pro­
duced. In addition, typical secondary antibody responses 
could be elicited from mice primed with antigen during 
macrophage impairment. Moreover, the macrophage toxins 
themselves appeared to be capable of priming mice for
95
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specific secondary responses to LPS. Thus, -it appeared that 
macrophages might have a role in modulating the immune re­
sponse in vivo by controlling the antigenic dose and pro­
moting long term stimulation rather than being absolutely 
necessary for "processing" the antigen,
Imoairment of in vivo nhagocvtic activity
Although there was no method available which would 
deplete completely the mice of macrophages it had been well 
established that silica and carrageenan were capable of 
selectively injuring and destroying substantial numbers of 
macrophages (2, 17). Numerous investigators have employed 
these agents, both in vivo and in vitro. to dissect the 
afferent and efferent limbs of humoral as well as cell- 
mediated immunity (8 52, 73» 92). However, despite the 
studies on immunological phenomenon in animals treated with 
silica or carrageenan, relatively little data had been 
accumulated on the degree and duration of impaired phago­
cytic activity iR vivo. Most commonly, the i.p. route of 
injection had been used for giving the macrophage toxins 
to test animals (40, 60, 92). It was possible that mate­
rials given by this route of injection could have damaged 
only the wandering mononuclear phagocytic cells and left 
the fixed macrophages intact. Dissemination of the i.p, 
injected toxin was considered to be dependent upon the 
ingestion of the cytotoxic particles by macrophages in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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route to other areas of the body. Persal and Weiser (60) 
were able to demonstrate disseminated silica particles 
within the spleen, liver and bone marrow of mice following 
the repeated i.p. injection of high concentrations of 
silica. However, no attempt was made to correlate the 
dissemination of silica particles with the reduction in 
phagocytic activity in vivo.
Impairment by MUS. In the present studies, when various 
regimens of MUS were given to mice by the intraperitoneal 
route, essentially normal carbon clearance values were ob­
tained. Since mice were exposed repeatedly to daily i.p. 
injections of MUS, it was felt that a sufficient amount 
(total dose of 250 mg) and time (6 days) was allowed for any 
dissemination to have occurred. The dissemination of MUS 
with resulting macrophage destruction was not detected by 
either in vivo carbon clearance studies or at autopsy.
Large quantities of MUS were found to be sequestered within 
the peritoneal cavity. Although microscopic examination was 
not performed, the MUS grossly appeared to be encased in a 
fibrous-like tissue membrane, often with adhesions to the 
liver, mesentery and peritoneal membranes. It had been well 
documented that silica-treated macrophages released a 
fibroblast stimulating factor (14, 49) which might have 
been responsible for the rapid sequestering of MUS given 
by the intraperitoneal route; this could allow for a quick
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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recovery of the RES.
The localization of MUS observed within the peritoneal 
cavity and the essentially normal carbon clearance data in­
dicated either that dissemination of a sustained cytotoxic 
concentration of MUS into areas where it could exert its 
effect on in situ macrophages did not occur, or else the 
release of MUS was slowed to a rate at which the host could 
compensate for its cytotoxic effects. In either case, the 
functional phagocytic capacity of the RES within the animal 
was not suppressed.
The ability of MUS injected intravenously to suppress 
the in vivo carbon clearance capacity of the RES correlated 
well with the results of other investigators (52). In the 
present study, RES suppression was observed by 2 h after 
mice were given i.v, doses of MUS. With a single treatment, 
the phagocytic capacity of MUS-treated mice remained sup­
pressed for days. Levy (52) had demonstrated previously 
that peritoneal mononuclear cells, harvested from mice 
treated with silica by the i.v. route, showed impaired 
phagocytosis of SRBC in vitro. Similarly in this study 
mononuclear cells, which were adherent to plastic and were 
obtained from the peritoneal cavity of mice treated with 
MUS i.v. 2̂ ■ h earlier, were less efficient in their ability 
to phagocytize Ç. stellatoideae cells in vitro. Thus, 
data were obtained from phagocytic studies in vivo and 
in vitro that the i.v. injection of MUS was capable of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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impairing the phagocytic activity of the fixed as well as 
the wandering macrophage populations.
Since MUS was not metabolized in vivo, it was thought 
that it could be used as a long term macrophage toxin. That 
is to say, after ingestion of the particle the macrophage 
would undergo autolysis releasing the toxic particle to be 
rephagocytized by other cells. This process would be re­
peated until the host could sequester the MUS in a fibrous 
or in a granulomatous lesion. However, this study demon­
strated that the suppressive effect of i.v, administered 
MUS on phagocytosis was maintained for only 4 days. There­
fore, it appeared that the toxic MUS particles were 
sequestered from the host rather quickly and the cytotoxic 
action either abolished or compensated for by the host. Re­
generation of a functional macrophage population, capable 
of yielding normal In vivo carbon clearance values, occurred 
within 5 days. Hence, a single injection of MUS could be 
used as a selective cytotoxic agent to evaluate the in­
ductive phage of immunological responses which occurred in 
less than 5 days, but this treatment could not chronically 
suppress macrophage function in vivo without repeated 
injections.
In summary, the MUS preparation employed within this 
study was capable of impairing the phagocytic capacity of 
the RES, It was found .that the i,p. route of injection for 
this macrophage toxin, even with multiple injections of high
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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doses (50 mg/day for 5 days) did not suppress the ability 
of the RES to remove carbon from the peripheral blood. 
Conversely, the i.v, administration of a single dose of 
MUS was found to suppress the ability of the RES to clear 
carbon as early as 2 h after its administration. Maximum 
impairment of phagocytic activity was obtained 6 h 
after the i.v. administration of MUS and this impairment 
was maintained for 4 days. Prom analysis in vivo and 
in vitro, it was shown that a substantial number of the 
phagocytic cells of the RES had been destroyed or im­
paired. From the above data, it was concluded that MUS 
could be used to analyze the role of macrophage phagocytosis 
in the induction of the immune response in vivo.
Impairment by carrageenan. Carrageenan, a high molecular 
weight polygalactose extracted from sea algae,was also used 
as a macrophage toxin in this study. It had been shown to 
exert its toxic effect by inducing changes in the permea­
bility of the lysosomal membrane resulting in autolysis of 
the phagocytic cell (2, 17),
Carrageenan was capable of suppressing the phagocytic 
activity of the RES when administered by either the i.v. 
or i.p. routes. However, mice would tolerate an i.v. dose 
of only 1 mg carrageenan, A solution of carrageenan was 
quite viscous even at low concentrations and the viscosity 
alone could have caused the deaths observed in mice which
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received 2 mg. Indirect evidence suggested that dissemi­
nation of the carrageenan occurred very rapidly throughout 
the host when the toxin was given i.p. Data in support of 
this, were from observations that suppression of the EES 
was observed within 2 h following i.p. injection of 
carrageenan.
Concurrently with the reduced carbon clearing capacity 
of situ macrophages, it was also found that the wandering 
macrophages harvested from the peritoneal cavity of mice 
treated with carrageenan were less effective in their 
ability to phagocytize in vitro. Therefore, as was found 
with T4US, carrageenan was also found to be capable of im­
pairing the phagocytic activity of the fixed as well as the 
wandering macrophage populations.
Changes in the serum enzyme concentrations of mice 
treated with either macrophage toxin also indicated that 
cell destruction had occurred. Weissman et al, (91) had 
shown previously that up to 25% of certain acid hydrolases 
were released from the lysosomes of phagocytic cells during 
phagocytosis. Hence, increased serum levels of enzymes 
normally contained within the lysosomes of phagocytes 
might not necessarily reflect cell destruction. Therefore, 
in this study both the lysosomal enzyme, acid phosphatase, 
and the cytoplasmic enzyme, LDH, were measured. Both 
enzymes were found to be elevated in mice exposed to macro­
phage toxins. The concomitant increase of both acid
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phosphatase and LDH indicated that the enzyme levels found 
in the peripheral blood were due to cell autolysis.
In addition, two other assay systems were used to 
demonstrate the in vivo cytotoxicity of MUS and carra­
geenan. The first system employed radiolabeled LPS in­
jected into normal and mice treated with the macrophage 
toxins. The tissue distribution of LPS found in normal 
animals correlated well with the results of other investi­
gators (11, 12, 5̂ , 68). It was demonstrated in this study 
that over 75^ of the LPS was found in the liver of normal 
mice, while less than \% was associated with any of the 
other tissues assayed. On the other hand, less LPS was 
found in the livers of mice treated with macrophage toxins 
and large amounts of LPS were retained in the peripheral 
blood of macrophage-impaired mice. Higher levels of LPS 
were consistently found in the spleens of macrophage- 
impaired mice than were found in normal mice. Thus, the 
treatment of mice with macrophage toxins had impaired the 
ability of the macrophages to phagocytize not only parti­
culate materials, such as carbon or yeast cells, but also 
the colloidal antigen (LPS) which was subsequently tested 
for immunogenicity in these mice.
The other auxiliary system used to demonstrate RES 
impairment was a measurement of the sensitivity of macro­
phage -impaired mice to the toxicity of LPS. It had been 
well established that agents which impaired the phagocytic
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activity of the RES increased the sensitivity of impaired 
animals to the toxic effects of LPS (6, 20), The results 
obtained in this study indicated that mice treated with 
MUS or carrageenan were respectively, 40 and 3000 times 
more susceptible than normal mice to the lethal effects of 
LPS.
Thus, by numerous independent assay systems this study 
showed that both MUS and carrageenan under controlled con­
ditions were capable of impairing the phagocytic capacity 
of the RES in a reproducible and consistent manner. This 
suppression was not permanent with either toxin, but it 
persisted for only 4 days. Maximal suppression of RES 
activity occurred 6 h after mice received either toxin and 
persisted at this level for at least 24 h and 48 h after 
treatment with MUS and carrageenan, respectively. There­
fore, it was felt that if mice were exposed to antigen 6 h 
after treatment with either macrophage toxin any role the 
macrophage might play in the afferent limb of humoral anti­
body formation should, be altered. If phagocytosis of anti­
gen was a prerequisite for the induction of an optimal 
immune response In vivo then mice receiving antigen during 
impaired phagocytosis should either (1) not be able to 
respond with antibody production, (2) respond with antibody 
production but, at a sub-optimal level, or (3) show a de­
layed antibody response until a competent macrophage
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population was regenerated.
Primary antibody responses
In other investigations (8, 52, 72, 80) it was observed 
that primary antibody responses could be suppressed in 
animals treated with agents which impaired the RES if the 
impairment occurred prior to immunization. Thus, it was 
inferred that phagocytosis, processing, and/or presentation 
of antigen to lymphocytes by macrophages were essential 
events for the induction of optimal antibody responses.
This study did not demonstrate any suppression of the pri­
mary antibody response to either LPS or SBRC antigens re­
gardless of the time at which mice were exposed to macro­
phage toxins in relation to the antigenic dose. The only 
observable difference between macrophage-impaired mice and 
normal mice was the increased primary antibody response of 
the impaired mice to low immunizing doses of the SRBC anti­
gen. This increased antibody response was induced only when 
mice were immunized 6 h and 24 h after exposure to macro­
phage toxins. Interestingly, this was the period during 
which the phagocytic capacity of the RES was most severely 
suppressed. Thus, it appeared that a decreased functional 
macrophage population in vivo could be correlated with the 
increased antibody response demonstrated in this study,
Keller (48) had shown with antibody responses generated 
in vitro that alteration of the macrophage/lymphocyte ratio
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could modify mitogen-induced lymphocyte proliferation, A 
macrophage/lymphocyte ratio of ten macrophages per one 
lymphocyte consistently blocked proliferation and even a 
ratio of one macrophage per one lymphocyte was inhibitory. 
Conversely, ratios of one macrophage per 25 or 100 lympho­
cytes resulted in an increased proliferative response.
Since both MUS and carrageenan have been shown to be 
selectively toxic for macrophages and not lymphocytes 
(2, 17) it could be assumed that the macrophage/lymphocyte 
ratio was decreased in treated mice. Thus, it appeared 
that there may have been a direct competition between macro­
phages and lymphocytes for antigen or that the macrophages 
suppressed proliferation of antigen-stimulated lymphocytes 
in normal mice.
When the tissue distribution of radiolabeled LPS was 
quantified, consistently higher than normal amounts of 
LPS were found within the spleens of macrophage-impaired 
mice. Similarly, others (75» 76) have demonstrated an 
increased localization of chromium-labeled SRBC within the 
spleens of macrophage-impaired mice. It appeared that 
if circulating antigen was not removed and sequestered by 
macrophages, it might be capable of binding directly to 
splenic lymphocytes.
In other investigations (8, 52, 72) it had been demon­
strated that the alterations in primary antibody responses
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of macrophage-impaired mice were correlated with both the 
routes of macrophage toxin administration and antigen pre­
sentation. Bice et al. (8) demonstrated normal to enhanced 
splenic PPG when SRBC antigen was given i.v. to mice 
treated previously with carrageenan i.p. However, when SRBC 
antigen was given i.p. to mice treated similarly with carra­
geenan, the number of splenic PPG was reduced greatly.
Other investigations (80, 81) also had demonstrated a de­
creased number of splenic PPG when both carrageenan and 
SRBC antigen were given i.p. It was concluded that the 
cytotoxic action of carrageenan was confined to the peri­
toneal cavity and did not affect macrophages throughout 
the animal. This allowed intravenously administered anti­
gen to be processed by the unaltered functional splenic 
macrophages. In opposition to the above data, the results 
of the present study indicated that carrageenan was not 
confined to the peritoneal cavity. In fact, its effect 
was disseminated rapidly throughout the host as evidenced 
by the impairment of intravenously administered colloidal 
carbon. An explanation for the decreased responses ob­
served in the previously cited work could be that 24 h 
following the i.p. injection of carrageenan, the predomi­
nant cell type within the peritoneal cavity was PMN, 
Therefore, the decreased anti-SRBG responses observed 
could have been due to antigen degradation by the PMN
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rather than the lack of macrophage processing.
In summary, other studies have shown that the injection 
routes of both the macrophage toxin as well as the antigen 
appeared to be critical in elucidating the role of the 
macrophage as an effecter cell of humoral immunity. Also 
recent studies by Benner and Vanoudenaren (7) demonstrated 
that the systems used for quantitative assessment of the 
immune response were important when attempting to evaluate 
the total humoral response. For example, specific PPG were 
found in substantial numbers in organs not normally 
assayed such as the bone marrow. The present investigation 
has demonstrated that primary antibody responses could be 
induced at normal or a supranormal levels during macro­
phage impairment. This was evaluated by determinations of 
the total circulating antibody response. It was felt that 
measurement of circulating antibody titers truly reflected 
the immunological status of the whole animal. Furthermore, 
it appeared that there might have been direct competition 
between macrophages and other immunologically active cells. 
This phenomenon was especially evident when macrophage- 
impaired mice were given a sub-optimal dose of SRBC, Thus, 
it appeared that macrophages could function to modulate the 
immune response in vivo by regulating the amount of antigen 
available for the triggering, rather than by some processing 
step. It also appeared that by controlling the amount of 
antigen available for antigenic stimulation, macrophages
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might play a major role in influencing the resultant class 
of antibody synthesized.
Secondary antibody responses
Relatively little data had been obtained from studies 
in vivo, which evaluated the ability of macrophage-impaired 
animals to be primed for secondary antibody responses, 
Stevenson and Stavitsky (79) demonstrated that the primary 
antibody response to T2 phage could be suppressed with 
anti-macrophage globulin (AHG), However, this regimen of 
AMG did not impair the secondary responsiveness of these 
animals. This indicated that if animals were immunized 
during impaired macrophage function the priming mechanism 
for secondary antibody responses was not affected.
Likewise, the present study demonstrated that mice 
treated with MUS or carrageenan before the primary immuni­
zation appeared to develop typical secondary antibody re­
sponses when challenged with a second dose of LPS. Since 
immunization with this regimen of LPS elicited anti­
bodies of only the IgM class, it was impossible to evaluate 
the secondary response by a change in antibody class. How­
ever, the kinetics and the magnitude of the response in­
dicated that a typical secondary antibody response to LPS 
had been elicited. Mice, primed during macrophage impair­
ment with varying doses of SRBC, responded with typical 
secondary responses when challenged with a second dose of
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SRBC. These antibody responses were characterized by an 
increased antibody titer and/or by antibody production of 
the IgG class. Thus, it appeared that priming with LPS or 
SRBC for a secondary antibody response occurred as effi­
ciently in mice which received the primary immunization 
during macrophage impairment as in normal mice.
In the course of running controls of the effect of MUS 
and carrageenan during the time of priming mice for sec­
ondary antibody responses, several observations were made. 
Mice treated with either toxin 21 days prior to immunization 
with SRBC developed higher than normal primary antibody 
responses. It was determined that macrophage-impaired mice 
responded with antibodies of only the IgM class, regardless 
of the immunizing dose. However, normal mice responded to 
a high dose of SRBC (0.2 ml of 10^) with both IgM and IgG 
class antibodies, whereas with a low immunizing dose of 
SRBC (0.2 ml of 0.05J») only antibodies of the IgM class were 
generated. This elevation of the antibody response in 
animals treated with macrophage toxins had been noted by 
others (33» 4-2, 46, 62), The present study did not evalu­
ate further the reason for the higher response obtained 
from mice exposed to macrophage toxins 21 days prior to 
immunization with SRBC.
More interesting were the observations made when mice . 
were exposed to macrophage toxins 21 days prior to
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immunization with LPS. It was noted that a secondary-type 
antibody response could be elicited with only one dose of 
antigen. From correlation of hemagglutination and PPG 
data, it appeared that this response might be due to in­
creased antibody production in committed lymphocytes rather 
than the development or expansion of a memory cell popula­
tion. Thus, regulatory factors which controlled the rate 
of negative feedback mechanism might have been altered by
(1) the decreased number of functional macrophages,
(2) factors released from the impaired macrophages, or
(3) the macrophage toxins themselves.
The possibility that B-cells were derepressed during
macrophage impairment or that major antibody production had 
occurred in organs other than the spleen could not be 
disregarded. Alternately, the possibility that the MUS and 
carrageenan preparations employed within this study were 
contaminated with LPS cannot be excluded totally. However, 
the fact that (1) anti-LPS titers could never be elicited 
from mice injected with only MUS or carrageenan, (2) direct 
anti-LPS splenic PPG were not demonstrated in mice receiv­
ing only MUS or carrageenan, (3) similar observations have 
been noted by other investigators (33) employing different 
antigens, and finally (4) the probability that both the MUS 
and carrageenan would be contaminated with the same chemo- . 
type of LPS made the possibility of LPS contamination very 
remote.
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As observed, in the present study, as well as in other 
investigations (46), immunization during macrophage 
impairment appeared to prolong the macroglobulin response 
to both LPS and SREC antigens. Consistently higher titers 
with evidence of IgM class antibodies were detected in 
macrophage impaired mice 21 days after immunization with a 
single dose of LPS or SRBC, Thus, especially when the 
anti-SRBC was evaluated, it appeared that the rate and 
duration of IgM production might be altered in mice exposed 
to macrophage toxins prior to immunization. The antibody 
response observed in normal mice appeared to involve a 
switch from the early biosynthesis of predominantly macro- 
globulin antibody to the production of 7 S molecules. Con­
versely, this switch to ? S antibody production did not 
occur as efficiently when mice were immunized during macro­
phage impairment.
Henry and Jerne (43) had shown that IgM could function 
as a positive feedback molecule. That is to say, antibody 
contained within the 19 S fraction when given prior to a 
moderate dose of SRBC antigen increased the antibody re­
sponse 10-15 fold. It appeared that the enhancement as well 
as the prolongation of the primary macroglobulin antibody 
response observed within this study might be directly re­
lated to the decreased functional macrophage population 
during immunization. Macrophages might function by
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controlling the epitope density of antigen available for 
triggering other cells in the immunological sequence. 
During macrophage impairment, antigen was not sequestered 
and, therefore, was available to repeatedly stimulate the 
immunological active cells. This repeated stimulation 
might result in the enhanced production of the positive 
feedback IgM molecule and may explain the enhanced, as well 
as the prolonged antibody responses observed in this study.
Concluding remarks
The precise mechanism by which macrophages partici­
pate in the immune response still remains to be eluci­
dated. From this study it appeared that macrophages may 
modulate, in vivo, the immune response by controlling the 
amount of antigen available for direct stimulation of other 
cells in the immunological sequence. Thus, the quantity 
as well as the quality of the immune response, may be con­
trolled indirectly by macrophages acting as a sequesterant 
of antigen and not by increasing directly the immuno­
genicity of the antigenic molecule via some processing 
step. These observations were consistent with current 
studies which indicated that a small amount of antigen 
remained on the surface of the macrophage and was not 
catabolized (88). Also, other studies demonstrated that 
macrophage-associated antigen could stimulate lymphocytes 
(y4, 78, 82). Such a mechamism would insure an economical
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response by reserving a small amount of antigen to stimulate 
the immune system over a prolonged period. Therefore, it 
appeared that phagocytosis, processing, and presentation of 
antigen by macrophages to lymphocytes were not prerequisites 
for the induction of immune responses in vivo. The role 
played by the macrophage would be one of a passive bystander 
rather than as an active participant.
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SUMMARY
The effects of macrophage toxins on the immune re­
sponse of mice in vivo were investigated,. It was deter­
mined that a reduction of the functional macrophage popu­
lation did not suppress the humoral immune response to 
either the T-cell independent LPS antigen or the T-cell 
dependent SRBC antigen.
Two specific macrophage toxins, MUS and carrageenan, 
were determined to be capable of reducing phagocytic 
activity in vivo. The degree of suppression varied with 
each toxin and depended on the route of administration.
TWS was capable of reducing phagocytic activity in vivo 
only when it was administered i.v. On the other hand, 
carrageenan reduced the phagocytic activity when administer­
ed either i.v. or i.p., although the i.p. route allowed the 
administration of a larger dose with fewer toxic side 
effects. The initiation and persistance of maximum impair­
ment of phagocytic activity in vivo was similar for both 
macrophage toxins. Maximum suppression was observed 
approximately 6 h after the administration of either toxin 
and recovery to a normal level of phagocytic activity oc­
curred after 5 days. Extensive analysis in vivo and in 
vitro by other parameters also indicated that mice exposed
114
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to MUS or carrageenan had impaired phagocytic activity.
The kinetics of the primary immune response to LPS 
were evaluated in mice treated with macrophage toxins.
Mice immunized with LPS during macrophage impairment were 
capable of producing antibody responses equivalent to those 
obtained in normal mice. There was no change in either the 
kinetics or magnitude of the antibody response in mice im­
munized during impaired macrophage activity. These results 
suggested that macrophages were not a critical cellular com­
ponent for the induction of humoral antibody responses to 
the T-cell independent LPS antigen.
The kinetics of the primary immune response to SRBG 
were evaluated in mice treated with macrophage toxins. It 
was demonstrated that mice immunized with SRBG during macro­
phage impairment were capable of producing antibody re­
sponses equivalent to or higher than those obtained in 
normal mice. Macrophage-impaired mice immunized with a low 
dose of SRBG (0.2 ml of 0.05^ SRBG) generated higher titers 
and demonstrated circulating antibodies 24 h earlier than 
normal mice. Macrophage-impaired mice immunized with an 
intermediate dose of SRBG (0.2 ml of 1% SRBG) responded with 
the generation of both IgM and IgG class antibodies.
Whereas, normal mice responded to this intermediate dose of 
SRBG with only IgM class antibodies. Thus, the class of 
antibody produced was dependent upon the immunizing dose
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of antigen as well as the functional macrophage population. 
These results suggested that macrophages were not essential 
for the induction of humoral antibody responses to the 
T-cell dependent SRBG antigen, in vivo. However, it appear­
ed that macrophages might compete with other cells for the 
quantity of antigen available for lymphocyte stimulation or 
that the macrophages suppressed proliferation of antigen- 
stimulated lymphocytes in normal mice.
Typical secondary antibody responses appeared to have 
been elicited from mice treated with MUS or carrageenan 6 h 
prior to primary immunization. Mice primed with varying 
doses to LPS during macrophage impairment and followed with 
a standard secondary dose of LPS 21 days later responded 
with a typical quantitative increase of IgM class antibodies. 
Mice immunized with varying doses of SRBG during macrophage 
impairment and 21 days later injected with a standard 
secondary dose of SRBG responded with a typical quantita­
tive increase of predominately IgG class antibodies. There­
fore, a reduction in the number of functional macrophages 
had not impaired the ability of mice to prime for secondary 
antibody responses.
In the course of running controls on the effects of 
MUS and carrageenan on priming for a secondary antibody re­
sponse several observations were made. Mice treated with 
either toxin 21 days prior to immunization with SRBG de­
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veloped higher than normal primary antibody responses to 
SRBC, It was determined that macrophage-impaired mice re­
sponded with antibodies of only the IgM class. However, 
the antibody response of normal mice was dependent upon the 
dose of SIÎBC administered. Normal mice responded to a high 
dose of SRBC (0.2 ml of 10$ SRBC) with both IgM and IgG 
class antibodies; with a low dose of SRBC (0.2 ml of a
0.5$ SRBC) only antibodies of the IgM class were generated.
More interesting were the observations made when one 
dose of LPS was given to mice exposed to macrophage toxins 
21 days prior to immunization with BPS'. It was noted that 
a secondary type antibody response could be elicited with 
only one dose of antigen. From correlation of hemagglutina­
tion titers and PFC data, it appeared that this response 
might be due to increased antibody production in committed 
lymphocytes rather than the development or expansion of a 
memory cell population. These secondary type antibody re­
sponses were not evaluated further.
It was also observed that immunization during macro­
phage impairment appeared to prolong the macroglobulin re­
sponse to both LPS and SRBC antigens. Consistently higher 
titers with evidence of IgM class antibodies were detected 
in macrophage-impaired mice 21 days after immunization with 
a single dose of LPS or SRBC. Thus, it appeared that the 
rate and duration of IgM production might be altered in
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mice exposed to macrophage toxins prior to immunization.
In summary, it appeared that macrophages were not 
critical cellular components of the ARU, It was demonstra­
ted in the present study that the induction of primary 
antibody responses, as well as the priming for secondary 
antibody responses, did not appear to be macrophage 
dependent. Prom the data obtained it appeared that macro­
phages might function in vivo by sequestering antigen and, 
thereby controlling the amount of antigen available for 
activation of other immunologically active cells rather 
than by increasing the immunogenicity of an antigen by some 
critical processing event.
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